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ABSTRACT 
Globally, 62% of 38 million HIV-infected people are receiving antiretroviral therapy. Inhibitors 
targeting the viral protease have been clinically successful as 9 protease inhibitors (PIs) have been 
approved by the FDA since 1995. However, drug resistance arising by mutations in the protease 
undermines effective treatment. Analysis of protease and its mutants by structural biology methods paired 
with enzymology has given insight into the molecular mechanisms for drug resistance and guided new 
strategies for inhibitor design. Recently, highly resistant variants of HIV-1 protease from clinical isolates 
have been identified with ~20 mutations and several orders of magnitude worse binding affinity for 
clinical PIs such as darunavir. Three such mutants, PR20, PRS17, and PRS5B, are the focus of this body 
of work and show 800-10,000-fold less susceptibility to darunavir than wild-type protease. 
Understanding the molecular mechanisms driving the extreme drug-resistance of these three 
protease mutants aid rational drug design efforts to fight the HIV/AIDS pandemic. 
Structure-guided strategies for drug design have resulted in an investigational inhibitor, GRL-
142, with modified ligands derived from the darunavir scaffold that shows 16-fold better inhibition than 
darunavir of resistant mutant PR20. The crystal structure of PR20 in complex with GRL-142 reveals how 
the expanded binding pocket, dynamic flaps, and faster dimer dissociation of PR20 are counteracted by 
the larger moieties of GRL-142.  
Resistant variant PRS17, which was rationally selected from the HIVdb genotype-phenotype 
database by machine learning, shows ~3-fold better inhibition by peptide substrate analogs compared to 
wild-type protease. Crystal structures of PRS17 with substrate analogs show a major effect of drug-
resistance mutations V82S and G48V improving interactions with substrates consistent with better 
inhibition, suggesting a novel mechanism for resistance.  
Finally, structural studies of another mutant selected by machine learning, PRS5B, reveal 
coordinated structural changes leading to decreased intra-subunit interactions and intermediate levels of 
resistance to PIs. The sum of knowledge on resistant variants PR20, PRS17, and PRS5B illuminates the 
evolution of HIV-1 protease in the era of accessible PI treatments. These results illustrate the power of 
combining structural analysis of proteins with enzyme kinetics for combatting drug resistant HIV.  
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1 INTRODUCTION  
1.1 Human Immunodeficiency Virus and AIDS 
Human Immunodeficiency Virus (HIV) is the etiological agent responsible for Acquired 
Immunodeficiency Syndrome (AIDS). No prophylactic vaccine for HIV is currently available 
and vaccine development remains a challenge1. Only two instances of long-term HIV remission, 
the famous London and Berlin Patients2–4, have been described, which occurred through bone-
marrow transplantation to treat cancer. Other than these exceptions, HIV infection is incurable 
and requires lifelong treatment. The World Health Organization (WHO) lists HIV/AIDS as one 
of the world’s most serious public health challenges and consequently recommends a 26.2 billion 
dollar global investment to reach 2020 targets5.    
1.1.1 From mysterious beginnings to pandemic 
Zoonotic transmission of the retrovirus from chimpanzees and gorillas to humans is 
speculated to originate from bushmeat practice6. Genetic studies place the most recent common 
ancestor of the most prevalent HIV subgroup (HIV-1 M) to ~1910 in what is now Kinshasa, 
Democratic Republic of the Congo7. From there, the first known cases of HIV disseminated 
through African colonialism-related urbanization, sex-trade, railways, and unsterilized medical 
activities in the 1920s8.   
Knowledge of the current outbreak of HIV began in 1981 in the United States as separate 
reports of rare Pneumocystis carinii pneumonia (PCP) lung infections and Kaposi’s Sarcoma in 
young men who have sex with men (MSM) and IV drug users9–11. Mysterious cases of immune 
deficiency were reported in Europe as early as March 198212–14. In September 1982, the United 
States Centers for Disease Control and Prevention (CDC) introduced the acronym AIDS to 
describe a defect in immunity associated with opportunistic infection primarily affecting MSM, 
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IV drug users, hemophiliacs, and Haitians with no known cause15. HIV was isolated from AIDS 
patients establishing the virus as the etiologic agent of AIDS in 198316–18. Not long after, HIV 
antibody detection was developed allowing HIV diagnosis prior to presentation of 
immunodeficiency symptoms as well as blood screening19,20. From 1983 to 1984, the number of 
deaths from AIDS cases in the US had nearly tripled from 1,292 to 3,66521 and by the end of 
1985, the WHO reported at least one AIDS case in every major region on Earth in their total 
count of over 20,300 infections22. 
The first HIV antiretroviral drug, a reverse transcriptase inhibitor named azidothymidine 
(AZT), was approved by the FDA to treat adults in 198723. However, HIV infection spread as 
researchers scrambled for new treatment options. By 1993, HIV infection was the leading cause 
of death among persons aged 25-44 in the US24. In June 1995, the first HIV protease (PR) 
inhibitor (PI), saquinavir (SQV), was approved by the FDA, ushering in the era of highly active 
antiretroviral treatment (HAART)25. The introduction of PIs in combination with other 
antiretrovirals brought about a drastic decrease in AIDS-related mortality26. 
When utilized properly, current pre-exposure prophylaxis (PrEP) and HAART treatment 
options have been successful at reducing sexual transmission of HIV in high risk groups27–29. 
However, sociopolitical and economic obstacles limit quality of life and treatment access for 
many infected individuals30. The United Nations Program on HIV and AIDS (UNAIDS) 
launched its ambitious 90-90-90 program in 2014 which aims for 90% of known infected 
individuals who are receiving antiretroviral therapy to have viral suppression31. In 
2018,UNAIDS reported more than 62% of infected individuals (~22.3 million) were receiving 
antiretroviral treatment globally32.  
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Widespread ART has fostered accumulation of drug resistance mutations for first line 
drugs leading to treatment failure33,34. The development of potent treatment options to combat 
drug-resistant virus is critical for continued success in suppressing the AIDS pandemic.            
1.1.2 HIV transmission and replication cycle 
HIV transmission often occurs via subclinically infected individuals because HIV is a 
lentivirus, a genus of retrovirus characterized by a long latency period. Infected individuals can 
rapidly accumulate large viral load for months or even years while remaining asymptomatic. 
This latency period is an important contributing factor in the spread of the virus across the globe.  
The virus can be transmitted by sexual and non-sexual means. HIV is sexually 
transmitted from infected individuals to uninfected individuals through transfer of blood, semen, 
and vaginal fluids. HIV can be transmitted non-sexually from an infected mother during 
pregnancy, birth, and breast milk. Parenteral exposure can occur through needle-sharing during 
injection drug use and in rare cases of blood transfusions and percutaneous needle stick. HIV is 
sexually transmitted from infected individuals to uninfected individuals through transfer of 
blood, semen, and vaginal fluids.   
Risk of sexual transmission is increased by individuals at a later stage of infection, sex 
act, higher viral load, and presence of other sexually transmitted diseases. Risk is decreased by 
condom use, male circumcision, PReP, and ART. A 2014 review by CDC researchers Patel et al. 
estimated per-act transmission probabilities for major exposure paths35. Per-act sexual 
intercourse transmission risk of HIV ranged from 0.04 to 1.38% with 99.2% attenuation with use 
of condoms and ART for the infected partner36. 
The current Prevention Access undetectable = untransmittable (U=U) campaign captures 
the current zeitgeist surrounding HIV treatment and transmission37. U=U describes HIV 
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treatment as a prevention strategy supported by 4 landmark studies showing that maintaining an 
undetectable viral load carries zero risk of HIV transmission in serodifferent couples during 
unprotected sex38–41. The treatment as prevention movement reinforces the need for effective 
ART for all at risk individuals in order to eradicate HIV.      
HIV transmission is dependent on the viral load in an individual42,43. High viral titers are 
a result of successful integration and replication of the virus in CD4+ T cells. Plasma HIV RNA 
levels are highest during the acute phase of infection (3-9 weeks after infection) then drop to the 
infection set point (4-6 months) for the chronic phase of infection (reviewed in 44). The 
progressive depletion of CD4+ cells leads to AIDS and chronic inflammation, risk of 
opportunistic infection, and oncological complication45.  
The basic replication cycle of HIV with major drug target steps46 is shown in figure 1.1 
and reviewed in detail by Freed in 47,48. An infectious HIV particle enters the cell through 
attachment between the envelope glycoprotein (ENV) with the cell CD4 receptor and either CC-
chemokine receptor 5 (CCR5) or the CXC-chemokine receptor 4 (CXCR4). The cell membranes 
of the incoming virion and target cell are fused together, and the viral core enters the host 
cytoplasm. The viral core is uncoated allowing the viral reverse transcriptase (RT) to convert the 
single-stranded, positive sense RNA genome into deoxyribonucleic acid (DNA). The viral DNA 
is then transported to the nucleus and the viral enzyme integrase (IN) inserted into the host DNA. 
The integrated provirus is able to serve as a template for human transcription machinery to 
generate viral RNAs. RNAs encoding the viral structure and enzymes (ENV, Gag, and Pol) as 
well as replication elements (Rev and Tat), are exported to the cytoplasm to be translated. The 
viral RNA genome is exported to the cytoplasm by Rev. New virus particles are produced when 
the Gag and Gag-Pol precursor polyproteins encapsulate the RNA genome, associate with ENV, 
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and assemble at the membrane using matrix protein (MA). A non-infectious immature particle is 
released in a process called budding. The final maturation step occurs when the viral HIV 
protease (PR) cleaves the Gag and Gag-Pol polyproteins into their individual viral components. 
Capsid (CA) and nucleocapsid (NC) encapsulate the RNA genome, RT, and IN forming a dense 
icosahedral core.  
The now infectious mature virion is free to infect a new cell. An infected cell and a 
mature virion in plasma have a half-life of 2.2 and 0.24 days respectively49. The HIV-1 particle 
generation time, from budding of infected parent cell to budding from a newly infected daughter 
cell, is 2.6 days50. In an infected individual, the replication process will produce an average 10.3 
billion HIV viral particles per day50. While ART is effective at inhibiting many steps in the HIV 
replication cycle, drug resistance51 and residual viral replication in sanctuary sites52 remain 
important issues for HIV research. 
Four classes of ART drugs target four stages of the HIV replication cycle (figure 1.1) – 
entry/fusion, reverse transcription, integration, and maturation. Most modern ART regimens use 
combinations of inhibitors for two targets. Recommended first line therapy for most people with 
HIV is an integration inhibitor plus two nucleoside-RT inhibitors53. Second line ART options are 
patient specific but often are protease inhibitor (PI) based53. Demand for second-line treatments 
is increasing. In sub-Saharan Africa, an estimated 4.6 million people, or 20% of those receiving 
ART, are expected to be receiving second-line ART in 2030 – a 5% increase from 202054.          
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Figure 1.1: Major events in the HIV replication cycle.  
After virion attachment and fusion, the viral core is released into the cytoplasm. The RNA 
genome is reverse transcribed into DNA which is then integrated into the host cell genome. 
Structural proteins and polyproteins are expressed and assemble at the cell membrane before an 
immature viral particle. Maturation via HIV PR processing of the Gag and Gag-Pol polyproteins 
produces a fully infectious HIV viral particle. Events outlined in red boxes are used as targets for 
inhibition by ART.     
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1.1.3 Current HIV prevalence and treatment accessibility 
ART is recommended for all patients with HIV as soon as possible in an effort to reduce 
risk of morbidity and transmission53. ART can be effective in suppressing HIV replication but is 
not a cure. Stopping ART will allow the infection to rebound within weeks55. Current guidelines 
emphasize the importance for educating patients on proper ART adherence to maintain viral 
suppression and minimize the emergence of drug resistance53.    
Figure 1.2 shows the global statistics for HIV prevalence, ART accessibility, and deaths 
related to HIV from 2000 to 201856. Right now, an estimated 37.9 million people globally are 
living with HIV and 23.3 million (62%) are accessing ART - up from 7.7 million in 201056. The 
increase in ART access has improved clinical outcomes. In 2018, 770,000 people died from 
AIDS-related illnesses, down 55% compared to peak in 2004 (1.7 million)56. 
Global ART accessibility has improved over time but all populations of HIV infected and 
at risk people must be treated in order to eradicate the disease57,58. Figure 1.3 shows current 
statistics for ART accessibility between major populations in the world56. These data are also 
tabulated for new infections and AIDS-related deaths in Table 1.156. The highest percentage of 
HIV-infected people accessing ART is in Europe and North America (79%). However, less than 
40% of infected individuals in Eastern Europe, central Asia, the Middle East, and North Africa 
are accessing ART. In the last two decades, prolonged ART has become an effective means to 
control the disease and early diagnosis and treatment allows people with HIV to enjoy a life 
expectancy close to the general population59–61.  
Key populations and their sexual partners accounted for the majority of new infections in 
201856,62,63. Key populations are defined by UNAIDS as MSM, sex workers, transgender people, 
injection drug users, and prisoners64. The risk of acquiring HIV is over 20 times greater than the 
8 
general population for MSM, injection drug users, and sex workers56. All populations across all 
regions must have HIV diagnostic tests and life-long accessible ART in order for eradication 
strategies to succeed65–68.                 
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Figure 1.2: Worldwide number of people living with HIV, accessing ART, and AIDS-related 
deaths from 2000-2018.  
Data adapted from UNAIDS at unaids.org, accessed 7/31/2019.   
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Figure 1.3: Number of people living with HIV and accessing ART for major geographical 
populations. 
Percentage indicates number of people living with HIV that are accessing ART. Data is tabulated 
in table 1.1. Data adapted from UNAIDS at unaids.org accessed on 7/31/2019.  
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Table 1.1: Regional census of people living with HIV, accessing ART, new infections, and 
AIDS-related death in 2018. 
Data adapted from UNAIDS at unaids.org accessed on 7/31/2019 
  
 
People 
living with 
HIV 
(million) 
People 
accessing 
ART 
(million) 
People living 
with HIV 
accessing ART 
(%) 
New infections 
(million)  
AIDS-
related 
deaths 
(million)  
Global  37.9 23.3 62 1.7 0.77 
Eastern and 
southern Africa 
20.6 13.8 67 
0.8 0.31 
Asia and the 
Pacific 
5.9 3.2 54 
0.31 0.2 
Western and 
Central Africa 
5.0 2.6 51 
0.28 0.16 
Latin America 1.9 1.2 62 0.1 0.035 
Europe and 
North America 
2.2 1.7 79 
0.068 0.013 
Eastern Europe 
and central Asia 
1.7 0.648 38 
0.15 0.038 
The Caribbean 0.34 0.187 55 0.016 0.0067 
Middle East and 
North Africa 
0.24 0.0788 32 
0.02 0.084 
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1.2 HIV Protease is an important drug target 
HIV-1 protease (PR), also referred to as retropepsin or HIV proteinase, is one of the most 
widely studied enzymes in history. PR was first identified in 1985 when the HIV genome was 
sequenced69 and quickly became an important target for inhibitors to prevent viral replication70. 
To date, the FDA has approved 9 protease inhibitors (PIs) for therapeutic use. The clinical 
success of PIs in combination therapy is considered a textbook example of the success of 
structure-based drug design71–74. Development of a new generation of PIs continues to innovate 
upon the success of current clinical drugs by improving drug potency and tolerability whilst 
combating drug resistant strains of PR75.        
1.2.1 HIV Protease function is essential for infectious virus 
As shown in Figure 1.4, PR induces viral maturation by cleaving the Gag and Gag-Pol 
polyproteins into individual structural proteins and enzymes required for infectious virus. 
Chemical inhibition and inactivating mutations of HIV PR were first shown to prevent 
production of mature infectious viral particles in 198876–78. Immature particles contain a 
spherical shell of Gag polyproteins with matrix protein (MA) bound to the lipid envelope. Capsid 
(CA) bridges MA and nucleocapsid protein (NC), which is bound to the viral RNA genome. 
Proteolytic maturation describes a process of the immature virus undergoing a morphological 
change into an infectious form. Mature viral particles have a condensed nucleoprotein core 
encapsulated by an icosahedral shaped fullerene-like shell. The shell is comprised of CA proteins 
hexamers with pentamers inducing curvature79,80.  
The 55 kDa Gag polyprotein consists of MA, CA, and NC structural proteins and the p6 
membrane-interaction protein81. During translation of Gag, a frameshift occurs 5% of the time 
which reads through a stop codon producing a larger 160 kDa polyprotein. The Gag-Pol 
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polyprotein contains a MA, CA, and NC with an attached PR, RT, and IN proteins. PR 
embedded in Gag-Pol has intrinsic activity and is released by an autoproteolytic process to 
produce mature PR82. During maturation, the junctions of each component in the Gag and Gag-
Pol polyproteins must be cleaved by the fully active PR dimer in a specific temporal and spatial 
processing cascade83. The timing of Gag and Gag-Pol processing must be coordinated with 
assembly and budding84. Furthermore, individual components must be processed and released in 
a specific order to allow for the structural rearrangement to occur within the small volume of the 
viral particle85. The cleavage order for the twelve different cleavage sites is regulated by the 
catalytic processing efficiency of PR for each site relative to one another48. In this way, HIV PR 
has been described as both a specific and non-specific enzyme. The direct involvement in HIV 
propagation makes PR an attractive target for antiviral inhibitors86.             
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Figure 1.4: HIV maturation occurs from cleavage of Gag and Gag-Pol polyproteins by protease 
A. Cartoon representation of the Gag and Gag-Pol polyproteins. PR cleaves the junctions 
between the individual structural and enzymatic components required for mature viral particles. 
sp=spacer peptide, TF=transframe protein. 
B. Electron micrographs and cartoon representations of HIV particles before and after 
maturation. The Gag-RNA polyprotein border of in immature virus converts to an icosahedral 
core after maturation to infectious virus. Micrographs adapted from Konvalinka et al. 2015. 
https://doi.org/10.1016/j.virol.2015.03.021.  
C. Cartoon of mature viral particle with labeled individual components. RNA genome colored 
orange.   
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1.2.2 HIV PR structure and mechanism 
The tertiary structure of PR is fundamental for both its proteolytic function, its affinity 
for inhibitors and its propensity to evolve resistance to PIs. The structure of PR is well 
characterized. Over 400 X-ray crystal structures of PR and numerous mutant variants are 
available on the Protein Data Bank (www.rcsb.org) with others withheld for proprietary reasons. 
Early efforts to biochemically characterize PR were hampered by the inability to generate 
enough protein sample for crystallization experiments87. On February 9th, 1989, Rous Sarcoma 
Virus (RSV) protease became the first retroviral protease reported88. Just 7 days later, a crystal 
structure of HIV PR was published by a group from Merck89. However, much of this structure 
was later retracted. The first fully correct structure, consistent with earlier molecular models90,91, 
was reported by Wlodawer et al. in August 198992. Later that year, a 2.7 Å PR structure was 
released by Lapatto et al. (1989)93. These structures not only opened the door to structure-guided 
drug design of PIs but also showed that chemically synthesized protein can fold correctly in the 
absence of ribosomes94. The first structure was monomeric and ligand-free and thus limited 
insights into the exact mode of substrate binding. The first dimer structure of PR with a ligand, a 
hexapeptide inhibitor (MVT-101), was reported later in 198995. Future structures with other 
ligands96,97 combined with analysis of the mechanism of ligand binding98,99 provided the 
foundation for rational drug-design of PIs100,101. Indeed, the PI Saquinavir (Ro 31-8959, Invirase) 
was studied by crystallography102 and FDA approved in 1995103.  
 HIV PR is an aspartic protease and its mature form has full catalytic activity as a 
homodimer. An illustration of PR dimer with PI is shown in figure 1.5. Two 99 amino acid 
subunits each contribute a catalytic triad (Asp25-Thr26-Gly27) to the active site for proteolytic 
function. The catalytic triad is highly conserved among aspartic proteases. The active site cavity 
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recognizes Gag, Gag-Pol, and Nef cleavage sites as decapeptides in subsites (S5-S5′). These sites 
are polymorphic104, however the consensus sequence for each cleavage site for the reference 
HIV-1 genome (HXB2)105 is shown in table 1.2. Subsites S2-S2′ are the target of competitive 
tight binding inhibitors currently used in the clinic.  
 In addition to the ligand binding and catalytic sites, the PR dimer contains intermolecular 
features important for its quaternary structure. For dimer stability, the N and C termini of each 
subunit form an intercalating β-sheet of antiparallel strands. This highly conserved interface is 
critical for dimerization106,107 as well as playing a role in autoprocessing108 and has long been 
considered a potential drug-binding site109–111. Other important dimer interface regions are 
internal hydrophobic contacts, hydrogen bonds in the “fireman’s grip” of the catalytic site112, two 
salt bridges (Arg8-Asp29′ and Arg87-Asp29′)113,114, and an interface at the tip of the flaps115. The 
latter interface is transient and only occur when the flexible flaps exist in a closed conformation, 
such as when PR is bound to substrate or inhibitor.   
 Each monomer contributes a mobile “flap” consisting of two antiparallel β-strands 
(residues 46-56) connected by a β-turn. The flap structures cover the active site cavity and act as 
a gate for entry of substrate or inhibitor. Proximal facing flap residues are important for substrate 
recognition and form direct interactions with inhibitors. The flexible flaps can move between an 
open and closed conformation116,117, however NMR studies reveal that wild-type PR in solution 
tends to exist in the closed flap conformation in the absence of inhibitor118. Each flap pivots 
about the “hinge-loop” (residues 34-41) which interface with the rest of the protease. Mutations 
in the flap and hinge regions have major implications in drug resistance119.    
 As an enzyme critical to the HIV life cycle, the structure of PR is linked to its substrate 
recognition and proteolytic functionality. As stated previously, PR must recognize a several 
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peptide substrates and cleave them at scissile bonds. Crystallography, both X-ray and neutron, 
has been a powerful tool to study the mechanisms of retroviral protease function by trapping 
different stages of the reaction120,121 and revealing the location of critical hydrogen atoms122–124. 
The mechanism of HIV PR proteolysis was most recently reviewed by Brik and Wong in 
2003125. Upon substrate binding to the active site, one of the catalytic Asp25 carboxylate 
sidechains is mono-protonated while the other is deprotonated126. The deprotonated aspartate acts 
as a general base to activate a lytic water molecule into attacking the amide-bond carbonyl-
carbon of the scissile bond127. A metastable gem-diol reaction-intermediate forms which is 
stabilized the primary protonated Asp25128–132. The gem-diol dissociates, breaking the scissile 
bond, and leaving two peptide products.  
Neutron structures of PR with inhibitors show that protonation of either the inner Oδ1 or 
the outer Oδ2 of Asp25 is dependent on the pH and chemical structure of the ligand123,124. 
Furthermore, the location of the hydrogen on Asp25 can be dependent on the protonation states 
of far-away residues133. Detailed knowledge of the PR structure, mechanism, and protonation 
states has provided valuable information for designing new PIs. 
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Figure 1.5: HIV-1 protease bound with inhibitor 
Wild-type HIV protease bound to protease inhibitor darunavir (PDB: 2IEN). Catalytic aspartates 
25/25′ (sticks), flexible flap regions, and terminal intersubunit β-sheets are labeled. Subunits are 
represented as blue and salmon cartoons with protein surface. Darunavir is shown complexed in 
the active site cavity as green sticks.   
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Table 1.2: Gag and GagPol cleavage site sequences.  
Peptide sequence of HIV-1 PR cleavage sites for HIV-1 PR reference genome HXB2. Sites are 
in genome order, not temporal order of cleavage. “|” represents the scissile bond. Adapted from 
Torrecilla et al. 2014.  
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1.2.3 Structure guided-drug design of protease inhibitors 
At present 9 drugs are approved by the FDA to target PR. Their chemical structures and 
year of introduction are provided in Figure 1.6. The first generation of inhibitors were influenced 
from the design of eukaryotic protease inhibitors and begun as transition-state mimics134. These 
designs were assisted by X-ray crystal structures of PR with different products135 but have been 
superseded by improved designs since. Ritonavir is still used a PI pharmacokinetic booster as it 
also inhibits cytochrome P450. 
The second generation of PIs were designed to target PRs with drug resistant mutations to 
the first generation of PIs. Lopinavir (LPV) was designed from Ritonavir (RTV) with the 
intention of minimizing influence of common drug resistance mutations at position 82135. 
Tipranavir (TPV) is the only non-peptidic PI and was discovered using high-throughput 
screening136. Darunavir (DRV) is the most recently introduced PI, reaching the market in 2006 
under the tradename Prezista. DRV is nearly identical to APV but has a bis-tetrahydrofuran 
(TFH) ring in place of a single TFH. DRV boasts the best affinity for wild-type protease with a 
ligand dissociation constant of 5pM137. DRV is the only PI with a favorable enthalpy and 
entropy-driven binding activity138.   
PI treatments have side-effects including dyslipidemia, metabolic syndromes, and 
cardiovascular and cerebrovascular diseases139. New inhibitors are required to not only combat 
drug resistance but to minimize side effects. Current drug-design strategies seek to build on the 
successful DRV scaffold to minimize off-target effects and inhibit drug-resistant PR. 
Understanding the differences between toxic and benign chemical groups used in PIs aids in 
minimizing off-target effects in future designs139. Newer compounds aiming to tie down the flaps 
in mutant PRs by adding hydrogen bonds with the flap main chain have shown promise140,141.     
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Figure 1.6: Clinical protease inhibitors of HIV-1 protease 
All PIs approved for therapeutic use by the FDA to treat HIV-1 infections in descending order by 
year introduced. Chemdraw templates kindly provided by Yuan-Fang Wang.   
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1.2.4 Drug resistance in PR 
HIV is highly heterogeneous in sequence thus is known as a quasispecies142. HIV-1 has 
low fidelity of replication that leads to spontaneous mutations capable of being selected upon 
when under drug pressure47,143. Low fidelity is caused by the viral reverse transcriptase (RT) 
lacking proofreading functionality144. In addition, RT naturally has low affinity for the for the 
RNA template causing template switches145 leading to genetic recombination if a viral particle 
has non-identical RNA templates146. These factors contribute to a spontaneous mutation rate of 
3x10-5 mutations per base pair per cycle of replication for HIV-1147 and make RT a critical drug 
target148. Mutation rates for HIV-1 PR are 3 and 7-fold greater than for spleen necrosis virus and 
bovine leukemia virus respectively147.      
Drug resistance for HIV-1 PR is defined as the ability of PR to process Gag and Gag-Pol 
substrate in the presence of a PI in vivo. The high mutation rate resulting from the native features 
of RT are a system-wide mechanism which initiates genetic variation allowing for rapid selection 
under drug pressure. PR specific resistance associated mutations (RAM) for protease inhibitors 
undergo positive selection by additional mechanisms. PR is prone to resistance due its dynamic 
and flexible protein structure149. In addition, the range of substrate cleavage sites recognized by 
PR necessitates a large ligand binding site. Insertions have been observed to play a role in drug 
resistance150–152. As resistance evolves, mutations can co-evolve in the Gag and Gag-Pol 
precursors that can compensate for lower catalytic activity of resistant PR153–155.    
Cultural and socio-political factors also contribute to drug resistance. Complications due 
to adherence to the antiretroviral program has implications for drug resistance156–158. Adherence 
can be compromised by patient non-compliance due to toxicity, side-effects, and the pill-
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burden159,160. Moreover, resistant strains can be directly transmitted from ART-treated patients to 
drug-naïve patients161,162.  
Drug resistance to protease inhibitors develops from mutations in the protease gene. 
Wensing et al.119 classifies mutations as either major or minor mutations; the current report 
designates over 30% of the protease amino acid positions to be associated with resistance to all 
FDA approved PIs. Major and minor RAMs are distributed throughout the PR protein163–165 
(figure 1.7) with major mutations yielding significant loss of effectiveness to single inhibitors 
and minor mutations thought to provide ancillary roles to major mutations such as compensating 
for loss of catalytic efficiency or stabilizing a destabilized region. PRs with single substitutions 
or a combination of RAMs have been studied using X-ray crystallography and enzyme kinetic 
techniques. Selected examples from the following three mechanism categories are described 
below: active site residues altering drug interactions, mutations reducing dimer stability, and 
distal mutations with unique mechanisms.  
 Substitutions of residues in the ligand-binding site cavity can alter PR-PI interactions. 
This can be a straightforward mechanism by which fewer interactions between the target and the 
drug reduce binding affinity. Hydrophobic residues such as Val32, Ile47, Ile50, and Val82 can 
commonly mutate to different hydrophobic side chains reducing PI affinity166. Mutation I84V is 
the only mutation considered major for all clinical inhibitors167. Smaller side chains at position 
84 are no longer able to make van der Waals interactions with inhibitors while maintaining 
affinity for substate168–170. The I47A major mutation for LPV produces two orders of magnitude 
worse inhibition for the inhibitor by reducing van der Waals contacts in the S2/S2′ subsites171. 
This effect was magnified by synergistic mutations V32I and I54V which alters the flap171. In 
double mutant with G48T and L89M mutations, altered side chains create an expanded ligand 
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binding cavity which confers resistance to SQV by a defective hydrophobic sliding 
mechanism172.  
 Since active PR binds PIs as a dimer, mutations increasing dimer dissociation can reduce 
inhibition by PIs via dissociation of the dimer-PI complex. PR dimerization occurs in two steps 
where intermolecular interactions at the active site bring subunits together for more 
intermolecular forces at the dimer interface to occur173. DRV and TPV can inhibit this 
dimerization process by binding to the monomer173,174. Thus, mutations disrupting dimerization, 
such as L33I/F can alter inhibition by DRV and TPV174,175. Ile50 at the flap tip contributes 
interactions to both PIs and intermolecular attraction and thus RAMs at this position fit into both 
of the above categories163.          
 Finally, mutations distal to the ligand binding site can induce loss of PI inhibition in 
diverse ways without directly contacting inhibitor. Major DRV and LPV RAM L76V has been 
well characterized in a series of crystallographic studies supported by molecular dynamics 
simulations176–179. A single carbon difference in the Leu76 residue shows resistance to inhibitors 
is conferred through lowered dimer stability, defects in auto-processing, and lost hydrophobic 
interactions at the flap-core interface. Distal mutation L90M is implicated in inducing small 
structural and dynamic changes that propagate throughout the PR to decrease PI binding180–182. 
Mutation G73S is a minor mutation associated with resistance to ATZ, APV, IDV, LPV, and 
SQV119. The serine substitution at position 73 sits along a β-strand away from the active site and 
initiates structural changes that propagate through residues Thr74 & Asn88 to Asp29 & Thr31 at 
the ligand binding site with implications for altered PI binding and substrate cleavage183.   
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Figure 1.7: Resistance associated mutations locations in the HIV-1 PR dimer 
Site of RAMs (spheres) on the PR dimer (pink cartoon) distributed across both subunits for 
clarity. Major and minor mutations are colored red and blue respectively. DRV is shown as green 
sticks. Adapted from Weber and Agniswamy (2009) and Weber, Kneller, and Wong-Sam (2015) 
using RAMs from Wensing et al.(2017).   
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1.2.5 Examples of highly drug resistant mutants 
Years of research into PR variants with 1-5 RAMs have given valuable insight into the 
different mechanisms by which mutations can alter PR-PI interactions, dimer stability, and 
substrate recognition. More recently, this foundation of work has allowed study of PR mutants 
with different combinations of approximately 20 mutations. These extreme PR variants often 
display several orders of magnitude reduced potency to multiple clinical PIs. Such highly-
resistant PR mutants share a PI-independent feature of altered flap conformations, but each 
employ unique and often synergistic mechanisms to evade inhibition by PIs. The following 
section will update and expound on an 2015 review of the subject165. Crystal structures of DRV-
bound examples of the highly resistant mutants described here are shown in figure 1.8 and the 
inhibition measurements of DRV for the mutants and amino acid substitution list are in table 1.3.   
An early look at multidrug resistant proteases was X-ray crystallographic studies on a 
clinical isolate dubbed MDR769. This PR mutant with 10 mutations, L10I, M36V, M46L, I54V, 
I62V, L63P, A71V, V82A, I84V, and L90M, has also been studied with an additional V82T 
mutant (MDR769 82T). Both MDR769 and the V82T variant display inhibition resistance to all 
clinical inhibitors184. The addition of the V82T mutation increases the resistance to DRV from 
2.8 to 11-fold relative to PR184. MDR769 has also been proposed to be resistant to dimerization 
inhibitors185. X-ray crystal structures of MD769 show an open flap conformation, disrupted 80’s 
loop, and perturbed S1/S1′ subsites186,187. The dual major RAMs V82A and I84V work in this 
structure to create a 3.0 Å expansion in the ligand-binding site188. Perturbations of the 80’s loop 
and flaps of MDR769 observed in the crystal structures are supported by NMR data189 and 
molecular dynamics simulations190.  
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An exhaustive enzyme kinetics, biochemical, and X-ray crystallography study was 
performed on another clinical isolate with 22 mutations referred to here as PR22 (T4S, L10V, 
I13A, K14R, K20I, A22V, L33I, E35D, M36I, N37D, R41K, K43S, G48A, I54V, I66F, H69K, 
T74S, V82A, I84V, L89I, L90M and T91S)153. This variant shows extreme inhibition resistance 
(>3,600 worse than PR) for SQV, RTV, IDV, and NFV but only 11-fold relative resistance to 
DRV (Ki = ~0.6 nM). A crystal structure of PR22 in complex with DRV at 2.1 Å resolution 
(PDB: 3T3C) shows changes in the flaps, hinge region, and S1/S1′ subsites. PR22 was isolated in 
2002 from a 10-year-old pediatric patient being treated with APV, LPV, and NFV yet failing 
ART with high viral titers and low CD4+ T-cell count. Changes in treatment regimen did not 
reduce accumulated RAMs in PR suggesting efficient viral replication during drug selection 
pressure despite mutations which reduce catalytic efficiency. However, PR22 in a HIV-1 subtype 
B displayed 3-orders of magnitude worse infectivity in in vivo experiments. Analysis of the 
patient Gag cleavage site sequences elucidated that mutations in the patient derived cleavage 
sites (p2-NC, NC-p1, and p6pol-PR) rescued virus infectivity. The HIV genome encoding PR22 
represents a coevolution of PR and Gag substrate to preserve viral fitness under drug-selection 
pressure. As of 2008, the patient was treated with DRV and showed improved CD4+ T-cell count 
demonstrating the value of improvements to PI design to combat drug resistance mutants.              
Several studies have been conducted on a clinical isolate with 20 mutations termed PR20. 
Isothermal Titration Calorimetry (ITC) show PR20 displays up to 8,000-fold worse binding 
affinity for DRV137 and cross resistance to clinical PIs APV and SQV191. Reduced affinity for PIs 
occurs through multiple synergistic mechanisms. Similar to MDR769 described above, PR20 
features an expanded ligand-binding pocket from the combination mutations I47V and I84V 
which reduce hydrophobic contacts with inhibitors192. PR20 also displays a 5-fold higher dimer 
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dissociation constant (Kd) compared to wild-type PR, which diminishes ability to retain 
inhibitors in the active site193. Finally, PR20 has altered flap dynamics relative to PR, as 
supported by several X-ray structures of PR20 with open and asymmetric conformations of the 
flaps192,194 in combination with NMR studies showing open conformation in the absence of 
inhibitor118, and multiple molecular dynamics simulations194,195. The extreme resistance 
exhibited by PR20 makes it an ideal prototype to assess how the next generation of 
investigational PIs perform against resistant protease. To date, three compounds have been 
discovered to inhibit PR20 proteolytic activity better than DRV (Ki for PR20 = ~40 nM). GRL-
50-10A and GRL-44-10A achieve Ki values of 1.7 and 4.3 nM respectively for PR20 stemming 
from the formation of new hydrogen bonds with Gly48140. GRL-142-13A (2) has a Ki of 2.5 nM 
for PR20196 and the details of its potency for PR20 relative to DRV are described in chapter 2.  
 A series of 6 multiple mutant PR variants with major RAMs for DRV (PRDRV1-6) were 
characterized in a pair of studies197,198. ITC data suggests these mutants lose susceptibility to 
DRV due to less-favorable enthalpy of binding compared to PR. Crystal structures of three of the 
mutants in complex with DRV show fewer H-bonding interactions relative to PR indicative of 
diminished enthalpy of binding.    
 The previously described PR drug-resistant mutants were chosen from correlation 
studies199 or broad enzyme kinetic experiments138. Alternative strategies for selecting mutant 
variants have produced mutants which have permitted new insights into PR drug resistance. 
Protease genotypes from databases are often from patients under selection pressure from multiple 
PIs during their lifetime which confound studies looking to study the accumulation of RAMs to 
specific PIs. In order to study the molecular mechanisms of resistance to a single inhibitor, 
laboratory selected PRs have been employed200. A laboratory-selected PR mutant with 4 RAMs 
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for DRV and 10 other substitutions (L10I, I15V, K20R, L24I, V32I, I33F, M36I, M46L, I54M, 
I63P, K70Q, V82I, I84V, L89M) was identified and termed P51. Ligand-free crystal structures 
of P51 show wider flap conformation compared to PR137. Inactive P51D25N crystallized in the 
presence of DRV displayed a remarkable mode of binding in which two inhibitor molecules are 
bound perpendicular to the typical orientation201.  
 Another strategy for selecting PR mutants for further study is machine learning based on 
a unified encoding of genotype-phenotype and structural data202–204. This approach has predicted 
representative sequences for high PI-resistance for further characterization. PRS17, a clinical 
isolate205 with 17 mutations (L10I, K20R, E35D, M36I, S37D, M46L, G48V, I54V, D60E, I62V, 
L63P, A71V, I72V, V77I, V82S, L90M, I93L) predicted to be resistant to 6 inhibitors is the best 
characterized. As predicted, all clinical PIs with the exception of TPV (which was not tested) 
show reduced potency for PRS17206. DRV has 10,000-fold worse affinity for PRS17 (KL = 50 
nM) despite the absence of any RAMs for DRV167. Like PR20, NMR experiments show PRS17 
also exists with an open flap conformation in solution in the absence of inhibitor, in contrast to 
PR which exists in the closed formation suggesting altered flaps as a mechanism for resitance118. 
Two X-ray crystal structures of ligand-free PRS17 show the flaps form a curled phenotype 
relative to PR118,207. The PRS17/DRV crystal structure reveals weaker binding of DRV does not 
occur through lost active site contacts. Furthermore, reduced peptide-analogs of the p2-NC and 
CA-p2 cleavage sites were measured to inhibit PRS17 3-fold better than wild-type207. Crystal 
structures of PRS17 in complex with p2-NC and CA-p2 elucidating PRS17’s enhanced substrate 
recognition are described in detail in chapter 3. Insights gleaned from studies on PRS17 
demonstrate the potential of this machine learning strategy for predicting representative 
sequences. Another mutant produced from this approach, PRS5B, is characterized in chapter 4.  
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  Highly-resistant HIV PRs often share altered flap conformational flexibility as a common 
mechanism for evading inhibition by PIs. The mutants described here use synergistic 
mechanisms to different degrees which lead to a range of magnitudes for reduced inhibition by 
PIs. All mutants in this list contained the common I84V mutation except PRS17. PR20, 
MDR769, and PR22 combine I84V with other smaller hydrophobic mutations to reduce van der 
Waals contacts with PIs through an expanded ligand-binding site. PRS17 and PR22 evolved 
greater recognition of substrates while PR20 possess a more stable monomer fold. Understanding 
of the molecular consequences of drug-resistance mutations is vital to designing new PIs against 
resistant PRs. Structural and biochemical characterizations of highly-resistant mutant exemplars 
provide valuable insight into the molecular mechanisms of resistance and prototypes to test 
investigational inhibiters.   
  
31 
 
Figure 1.8: X-ray crystal structures of highly-resistant PR mutants in complex with DRV 
Cα of substituted amino acids are shown as grey spheres. Major and minor mutations for DRV 
are colored in red and blue respectively. DRV is shown as green sticks.   
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Table 1.3: Highly-resistant PR mutants and inhibition values for DRV. 
Mutants are in descending order by relative resistance to DRV. Major and minor mutations for 
DRV are colored in red and blue respectively. Inhibition measurements are from ITC and kinetic 
measurements under different conditions and may not be directly comparable. As defined by 
Wensing et al. (2019), major mutations for DRV are I47V, I50V, I54M/L, L76V, & I84V. Minor 
mutations for DRV are defined as V11I, V32I, I33F, T74P, & I89V.  
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1.3 X-ray crystallography and structural biology 
1.3.1 Crystallography for biology – a brief history 
German astronomer and mathematician Johannes Kepler first described crystals in a 
scientific context in 1611 in his Latin essay A New Year's Gift of Hexagonal Snow, or On the six-
cornered Snowflake208. X-rays also known as Röntgen radiation were defined in 1896 when 
German physicist Wilhelm Röntgen published a radiograph of his wife’s hand in Science209. It 
was not until the 1915 Nobel Prize in Physics awarded work by William Henry Bragg and 
Lawrence Bragg that the potential of X-ray diffraction from crystals was fully realized210. The 
field and size of molecules studied grew rapidly from solving the structure of NaCl211 and 
diamond212 in 1914 to the first small molecule, hexamethylenetetramine, in 1923213. Sperm 
whale myoglobin was the first protein structure solved by X-ray crystallography in 1958214. 
British chemist Dorothy Crowfoot Hodgkin pioneered X-ray crystallography for protein and 
biological molecules by solving the structure of cholesterol, penicillin, vitamin B12
215, and 
insulin216 earning her the Nobel Prize in Chemistry in 1964. Perhaps the most famous discovery 
from X-ray crystallography is the understanding of the double helical structure of DNA in 
1953217 when James Watson and Francis Crick obtained Rosalind Franklin’s X-ray diffraction 
image of DNA from Maurice Wilkins.  
At present, high resolution macromolecular X-ray crystallography is practiced at 
synchrotron radiation beamlines218. Approximately 140,000 structures of protein, nucleic acids, 
and protein-nucleic acid complexes have been determined by X-ray diffraction methods to 
date219. The frontier challenges of macromolecular crystallography research are being met by 
subatomic resolution with X-rays and direct hydrogen atom determination using neutron 
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diffraction220. To meet the need for high quality protein crystals, researchers and astronauts are 
even growing protein crystals in microgravity on the international space station221.   
1.3.2 X-Ray crystallography 
An overview of a typical X-ray crystallography experiment is presented in figure 1.9. 
Protein crystals for X-ray crystallography are commonly grown using vapor diffusion 
techniques222. In a classic vapor diffusion crystallization experiment, purified protein is mixed 
with buffer containing precipitating salts and allowed to equilibrate in a system containing a 
reservoir of the same buffer at higher concentration223. As water molecules diffuse from the 
protein-buffer drop, the protein and precipitant concentrations in the drop gradually increase. 
Protein molecules may begin to aggregate in a crystalline form if the precipitant, temperature, 
pH, additive, and temporal conditions are correct224. Protein crystals are generally cryo-preserved 
in liquid nitrogen prior to shipping to synchrotron beamlines to reduce data noise, radiation 
damage, and transportation-related trauma.  
For X-ray diffraction data collection, crystals are rotated about an axis using a 
goniometer while subjected to an X-ray beam wherein electrons from atoms in the molecule 
scatter the beam. Large ordered array of protein molecules from the crystalline form serve to 
amplify the signal intensity. Image sensors collect the X-ray diffraction pattern to be analyzed. 
The reflection pattern is a reciprocal lattice of the molecule crystal lattice and must be converted 
to structure factors, the amplitude and phase of the diffracted X-ray waves, in order to be 
interpreted visually as electron density maps. Amplitude information is gathered by the intensity 
of each spot in the pattern. Information on the phase of the X-ray wave for diffracted spots is 
determined by different means. The diffracted spots are related to the electron density of the 
crystal unit cell by a Fourier transform225. If the structure of a similar protein has already been 
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determined, the “phase problem” may be solved by an approach called molecular replacement226. 
Structure factors from the three-dimensional features of the known molecule are calculated for 
rotations and translations. Structure factors in agreement with the experimental diffraction data 
allow orientation of the molecule the unit cell to be estimated. This orientation is then tested for 
different positions in the unit cell. Orientation and translation models which agree with the 
experimental data are used to calculate phases. Other methods to determine phases for 
macromolecular diffraction patterns are multiple isomorphous replacement227 and 
multiwavelength anomalous dispersion228. From structure factor information, electron density 
maps may be calculated and an atomic model interpreted229.     
 
  
36 
 
  
Figure 1.9: Overview of the protein X-ray crystallography process 
In a typical X-ray crystallography diffraction study, protein crystals are grown, cryoprotected 
and sent to an X-ray source such as a synchrotron. X-ray scattering from the crystal is collected 
and processed to produce an electron density map (blue mesh in 5). The atomic model is built 
and refined to produce a final structure used for biological analysis.  
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1.3.3 Complimentary protein structural biology techniques 
Single crystal X-ray diffraction is powerful and vetted technique to reveal the three-
dimensional structure of proteins but possesses inherent limitations. The technique requires 
crystals suitable for diffraction, which are challenging to grow for intrinsically disordered 
proteins230 and large proteins with transmembrane domains231,232. Protein preparation and the 
crystallization process can introduce artifacts that may not represent the physiologically relevant 
conformation of the native protein in solution233. Furthermore, low X-ray scattering power of 
hydrogens necessitates that hydrogen positions must be inferred or estimated. Luckily, these 
limitations can be countered using complimentary structural biology techniques.  
Neutron crystallography is the forefront approach for determination of hydrogen position 
in protein structures. Neutron scattering is similar to X-ray crystallography and the 
complimentary results of the two diffraction experiments on the same crystal are often 
combined234,235. Neutrons scatter from atomic nuclei and permit room temperature data 
collection without destroying the crystal or producing artifacts associated with X-ray scattering. 
Hydrogen nuclei and heavy atoms have similar neutron scattering length, rendering hydrogens as 
visible as carbon, nitrogen, and oxygen. The caveat is that neutrons scatter with high inelastic 
scattering from protium nuclei giving high background. Perdeuteration or hydrogen-deuterium 
isotope exchange of the protein crystal sample can improve signal-noise ratios because 
deuterium offers the same scattering length with lower incoherent scattering than protium236.  
With clear advantages over X-ray crystallography, neutron diffraction has key limitations 
to overcome before becoming widespread. Chiefly, access to neutron source resources for 
crystallography is scarce with less than 25 neutron sources on Earth and even fewer single-
crystal neutron diffractometers. In addition to lower resolution data sets compared to X-rays, 
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large crystals (>1-10 mm3) and long data collection time requirements bottle-neck neutron 
structures, although higher flux neutron beams and improved detection instruments are 
addressing these concerns237. Combining the high-resolution heavy atom determination from X-
ray crystallography with the hydrogen sensitivity of neutron diffraction offers a complete picture 
of atomic positions within a protein crystal.    
Small angle X-ray scattering (SAXS) and small angle neutron scattering (SANS) are 
diffraction techniques which provide low resolution structural information for a protein in 
solution. Small angle scattering experiments record X-ray or neutrons scattered from protein in 
solution at angles less than 10º. These results allow interpretation of a protein envelope in 
solution without a crystallization238. SAXS and SANS yield information for protein size, shape, 
and surface-volume ratio to be determined239,240 and are useful for validating complimentary 
structural biology technqiues241. Small angle scattering requires extremely pure protein samples 
at greater concentrations than for crystallization experiments242.        
Solution NMR spectroscopy is another valuable technique for studying protein 
conformations in solution243. Protein NMR takes advantage of changing atomic nuclei spin states 
for isotopes of biological important nuclei when a magnetic field is applied244. Information 
gathered in NMR spectroscopy experiments show an ensemble of conformations of proteins in 
solution and dynamic motion. NMR is useful for small proteins (<50 kDa) that resist aggregation 
at high concentration244. 
Structural techniques discussed here are extremely useful for single proteins such as 
enzymes, yet many of the most complex biological systems involve large multi-protein 
complexes. Where crystallography falls short in this regard, the rapidly advancing field of 
Cryogenic electron microscopy (Cryo-EM) permits structure information for large complexes in 
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solution. For example, cryo-EM tomographic information has provided never-before-seen details 
of the envelope of HIV245, Zika246, and dengue virus247. Improvement in image detection and 
dedicated Cryo-EM analysis packages will prove useful for determination of Cryo-EM structures 
in the future248.       
Structural biology techniques have been facilitated by advances in computer science. 
Molecular dynamics (MD) simulations of protein structures sit at the axis of the two disciplines 
to enable new understanding of protein structure data. MD is used to simulate the physical 
interactions of atoms in a system to predict the trajectories of those atoms over a time period249. 
Molecular mechanics are applied to all atoms a system to build molecules proteins, ligands, and 
solvent. From MD simulations, one can generate predictions of ligand binding energy, local and 
global protein dynamics, and electrostatic interactions250,251.     
The platform of complimentary techniques used in structural biology is employed for 
characterizing the three-dimensional properties of biomolecules. Evidence of the field’s utility 
can be appreciated in contributions to areas such as drug-design252, synthetic biotechnology253, 
bioremediation254, and oncology255. The protein structure-function information gathered by 
structural biology techniques are paramount to understanding how biomolecules are created, 
converted, and can be manipulated to human benefit.      
1.4 Overview of Aims 
The HIV/AIDS pandemic is nearing 40 million infected individuals. The viral PR, 
essential for virion maturation and infectivity, is a key target for competitive inhibitors approved 
by the FDA to treat HIV infection. PR evolves RAMs over time in PI-treated patients which 
threaten viral suppression status, necessitating continued development of treatment options. 
Understanding protease-inhibitor interactions in examples of HIV resistant mutants aid design of 
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the next generation of PIs. The overarching hypothesis is that the primary contributor to PI 
resistance is the structural and dynamic modifications that result from mutations in HIV-1 PR. In 
this body of work, X-ray crystallography and enzyme kinetic techniques were used to elucidate 
the molecular basis of PI-resistance for three highly resistant PR mutants (PR20, PRS17, and 
PRS5B) to assist rational design of new inhibitors.     
1.4.1 Aim 1 
To compare the effectiveness of investigational protease inhibitor GRL-142 with 
clinical inhibitor darunavir for inhibiting the drug-resistant HIV-1 protease mutant PR20. 
Enzyme kinetic inhibition measurements indicate GRL-142 inhibits PR20 better than does DRV. 
A high-resolution crystal structure of PR20 complexed with GRL-142 compared to PR20/DRV 
suggests the improved inhibition stems from greater favorable interactions with PR20. GRL-142 
represents a successful case of structure-guided drug design to combat resistant PRs.     
1.4.2 Aim 2  
To investigate the molecular mechanisms of substrate binding to drug-resistant 
HIV-1 protease mutant PRS17. Reduced peptide analogs of the Gag p2-NC and CA-p2 
cleavage sites show 3-fold better inhibition of resistant mutant PRS17 proteolytic activity than 
for wild-type PR. Crystal structures of PRS17 bound to p2-NC and CA-p2 reveal that enhanced 
substrate recognition is driven primarily by active site mutations G48V and V82S altering 
PRS17-Substrate interactions. This study highlights a dual-resistance mechanism of G48V and 
V82S to evade interactions with PIs and enhance substrate binding.               
1.4.3 Aim 3 
To characterize the enzyme kinetics, inhibition, and inhibitor-bound X-ray crystal 
structures of drug-resistant HIV-1 PR mutant PRS5B. Enzyme kinetics data confirm 
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resistance data in HIVdb by showing that a PR mutant, PRS5B, exhibits intermediate levels of 
inhibition by clinical PIs. A urea denaturation assay indicates PRS5B, PRS17, and PR20 have 
comparable catalytic activity to wild-type in the presence of a chaotropic agent. Crystal 
structures of PRS5B in complex with APV and DRV reveal clusters of mutations in distal 
regions act synergistically to decrease intra-subunit interactions with respect to equivalent wild-
type PR structures. Molecular dynamics simulations of ligand-free enzymes show more dynamic 
flaps and conformational variability for PRS5B than for PR, consistent with increased 
dissociation of inhibitors. PRS5B shares common traits with other resistant mutants but also 
possesses mutations with opposing effects suggesting it has not evolved to produce the high 
levels of resistance seen for other mutants.    
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2 POTENT ANTIVIRAL HIV-1 PROTEASE INHIBITOR COMBATS HIGHLY 
DRUG RESISTANT MUTANT PR20 
Kneller DW, Agniswamy J, Ghosh AK, Weber IT (2019) Potent antiviral HIV-1 protease 
inhibitor combats highly-drug resistant mutant PR20. Biochemical and Biophysical Research 
Communications. (519)61-66.  
2.1 Abstract 
Drug-resistance threatens effective treatment of HIV/AIDS. Clinical inhibitors are 
ineffective for highly resistant protease mutant PR20, however, antiviral compound 2 with fused 
tricyclic group at P2, extended amino-benzothiazole P2’ ligand and two fluorine atoms on P1 
shows 16-fold better inhibition than darunavir of PR20 enzyme activity. Crystal structures of 
PR20 and wild-type PR complexes reveal how the extra groups of 2 counteract the expanded 
ligand-binding pocket, dynamic flaps, and faster dimer dissociation of PR20. 
2.2 Introduction 
The HIV/AIDS pandemic comprises about 38 million infected individuals with almost 
60% receiving antiretroviral therapy56 and showing decreased mortality5. This success is 
undermined by treatment failure due to drug resistance and persistent reservoirs of latent virus256.  
Antiviral HIV-1 protease (PR) inhibitors (PIs) are effective for therapy, and darunavir 
(DRV, 1) (Figure 1) is approved for first line treatments257,258. Its favorable properties include 
picomolar affinity for PR, high genetic barrier to resistance259,260, inhibition of precursor 
autoprocessing137,261 and inhibition of PR dimerization262. Nevertheless, DRV-resistant viral 
strains pose a problem263. Resistance to PIs evolves primarily by mutations in PR. Mutations of 
>35 of the 99 residues in PR are associated with resistance to one or more PIs164. Highly-
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resistant PR variants in clinical isolates have different combinations of about 20 mutations and 
diminish the effectiveness of PIs by a variety of molecular mechanisms118,153,165,187,206.  
An HIV-1 PR variant with 20 mutations derived from a clinical isolate (PR20) has been 
characterized and used as a prototype to assess investigational PIs138,192. Compared to wild-type 
PR, PR20 shows drastically reduced inhibition by clinical PIs with over 8,000-fold worse 
binding affinity for DRV137. Moreover, autoprocessing of its precursor is unaffected by 1 unlike 
the wild-type precursor137. Structures of PR20 reveal an expanded ligand-binding cavity, which 
contributes to decreased affinity for PIs192 and fewer interactions with substrate analogs. 
Crystallography and NMR spectroscopy experiments suggest a PI-independent mechanism for 
poor PI affinity due to increased mobility of the two flexible flap regions192,194,195,264. Finally, 
PR20 has a higher rate of dimer dissociation than wild-type enzyme, which further weakens drug 
binding193. PR20 contains four mutations in the ligand binding site (D30N, V32I, I47V, I84V) 
which act in the S1/S1′ and S2/S2′ pockets to decrease hydrophobic interactions with 
inhibitors191,192. The dimer structure of PR20/1 and key mutations are shown in Figure 1B. PR20 
provides an excellent prototype to assess the effectiveness of new inhibitors designed to combat 
highly resistant variants140,191.  
Potent new PIs are urgently required to target resistant variants such as PR20, but must 
also feature improved genetic barrier to resistance and better CNS penetration265 for effective 
treatment. Recently, antiviral compound GRL-142 (2) was reported to show picomolar inhibition 
of PR activity, high barrier to resistance, and improved penetration of the blood-brain barrier 
compared to 1266,267. Compound 2 was designed with modifications of three moieties of DRV 
(Figure 1A) to target drug-resistant variants268: P2 bis-tetrahydropyranofuran (bis-THF) is 
replaced by a “crown-like” Crn-THF; P2′-aniline is substituted by a cyclopropyl-amino-
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benzothiazole (Cp-Abt) group, and two fluorine atoms modify the P1-phenyl group to create bis-
fluoro-benzyl (bis-FBz). Fluorination of PIs has been shown to introduce halogen-bonds with 
protease140,269 and increase lipophilicity141,270.    
Here we report that 2 is an order of magnitude better than 1 in inhibiting enzyme activity 
of drug-resistant PR20. The crystal structure of PR20/2 complex reveals how the inhibitor 
effectively fills the expanded ligand binding site and stabilizes the dynamic flaps and dimer 
interface.  
2.3 Methods 
2.3.1 PR20 expression and purification 
 A synthetic 99 amino acid gene derived from the clinical isolate for PR20138 was 
expressed in E. coli, purified, and folded as described in 192. 
2.3.2 Kinetic inhibition assay 
Compound 2 (>95% purity by HPLC) provided by Dr. Arun Ghosh at Purdue University 
was dissolved in 100% DMSO. The kinetic inhibition value (Ki) of 2 for PR20 was measured 
using a FRET-substrate (BACHEM H-2992) at 37°C and pH 5.6 based spectroscopic assay as 
described in 207. 
2.3.3 X-ray crystallography 
PR20 at 4 mg/mL was mixed with 2 at 1:5 molar ratio. Crystals were grown using 
hanging-drop vapor diffusion in 1.8 M sodium chloride, 0.1 M sodium acetate pH 5.5, 0.1 M 
yttrium chloride, and cryo-protected in mother liquor containing 30% glycerol prior to freezing 
with liquid nitrogen. Diffraction data were collected on the SER-CAT 22ID beamline at the 
Advanced Photon Source, Argonne National Laboratory (Argonne, IL). X-ray data were 
processed and scaled using HKL-2000271 before solving the structure by molecular replacement 
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in phaser272 from CCP4273 with PR20/GRL-5010A (4YHQ)140 as initial model. The structure was 
refined using COOT274 and REFMAC5275 applying anisotropic B-factors. Hydrogen bonds (2.4-
3.5 Å) and hydrophobic contacts (3.6-4.2 Å) were inferred from interatomic distances and 
chemistry. Figures were generated using PyMOL276. Coordinates and structure factors for 
PR20/2 have been deposited in the Protein Data Bank with accession code 6PRF. 
2.4 Results 
2.4.1 Compound 2 is more effective than DRV for PR20 
Investigative compound 2 has an enzyme inhibition constant (Ki) of 14 pM for wild-type 
PR266, comparable to the value of 5-10 pM for the best clinical inhibitor, DRV277,278. 2 exhibits a 
Ki of 2.5 ± 0.5 nM for PR20, approximately 1200-fold worse than for PR. However, this Ki for 
PR20 is 16-fold better than the 40 nM value observed for DRV137. 
2.4.2 Overall structure of PR20/2 
The crystal structure of the PR20 complex with 2 was refined to a R-factor of 15.2% at 
1.21 Å resolution, the highest resolution to date for PR20 (Table 1). The asymmetric unit has a 
homodimer of PR20 (residues 1-99 and 1′-99′). Inhibitor 2 binds in the active site in two 
orientations with 0.5/0.5 relative occupancy related by ~180° rotation. An Fo-Fc omit map for 
one conformation of 2 is shown in Figure 2A. Residues 45-47, 50-51, 44′-48′, and 50′-52′ in the 
flap region, Asn30/30′ and Arg8/8′ also show two alternate conformations, each associated with 
one inhibitor orientation. The two alternate conformations show no significant differences in 
PR20 interactions with 2. Inhibitor-binding interactions in PR20/2 were compared with those in 
PR/2 and PR20/1 complexes. 
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2.4.3 Mutant PR20/2 compared to wild-type PR/2 
The PR20/2 structure was compared to two reported structures of wild-type PR/2. The 
equivalent 198 Cα atoms of the two PR/2 (6BZ2, 5TYS) dimers266,267 superpose onto PR20/2 
with Root mean square deviations (RMSDs) of 0.63 and 0.68 Å, respectively. The two PR/2 
dimers are nearly identical (RMSD = 0.48 Å) with two conformations for 2 of almost equal 
occupancies. For clarity, the following analysis will describe significant differences in one 2 
conformation in comparison to the major occupancy conformation of the higher resolution PR/2 
(6BZ2 at 1.67 Å) structure.  
Polar interactions between PR20 and 2 are shown in Figure 2B. The wild-type PR/2 
complex has almost identical hydrogen bond and halogen interactions except for interactions 
with the mutated residue D30N. Polar and non-polar interactions are described separately for P2 
and P2’ groups.   
The bulky P2-Crn-THF on 2 binds in the S2 pocket (Fig 3A), where the two oxygen 
atoms form three hydrogen bonds with main-chain amides of residues 29 and 30 in both PR and 
PR20. The D30N mutation in PR20 substitutes a carboxylic acid for a carboxamide side-chain 
which enables formation of a 3.5 Å hydrogen bond with 2 which cannot occur for Asp30 in the 
PR structures. The P2-Crn-THF packs into the hydrophobic pocket of the S2 site forming 3 van 
der Waals contacts with Ile47 in PR. The S2 pocket of PR20 contains the drug-resistance 
mutations I47V and V32I. Mutation I47V produces one less hydrophobic contact, while the 
longer isoleucine side-chain in V32I introduces 3 new van der Waals contacts with 2 that are 
absent in PR. This observation is consistent with molecular dynamics simulations showing 
improved van der Waals interaction energy between a V32I single mutant and 2267. Therefore, 
the three drug-resistance mutations in the S2 pocket of PR20 result in a net increase of one 
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hydrogen bond and 2 hydrophobic interactions with the P2 group of 2 in comparison to those in 
the wild-type complex PR/2.  
In the opposite protease subunit, the P2′-Cp-Abt group of 2 binds in the S2′ pocket (Fig 
3B). In the PR/2 structure, the side-chain carboxylate of Asp30′ forms a bifurcated hydrogen 
bond with the two nitrogen atoms of Cp-Abt. In PR20, the side-chain of the mutated D30′N is 
flipped 180° relative to its conformation in the other subunit. This orientation of Asn30′ forms a 
hydrogen bond with the P2′ amine of 2, while also forming a hydrogen bond with the aspartate 
side-chain of N88′D in PR20. The B-value for Asn30′ side-chain in PR20/2 is approximately half 
that of Asp30′ in PR/2 and PR20/1 (16 vs 33 and 28 Å2), suggesting a more stable conformation. 
The main-chain of Val47′ in the PR20 flap is shifted by 0.5 Å relative to its position in PR, 
eliminating a hydrophobic interaction with the thiazole sulfur of 2. However, the cyclopropyl 
moiety on 2 is shifted 1.5 Å towards the I47′V mutation, which introduces two hydrophobic 
contacts. Like in the S2 pocket, the larger V32′I mutation introduces a hydrophobic contact with 
2. Thus, PR20 shows favorable polar and hydrophobic interactions with the P2′ group of 2 
despite multiple resistance mutations in the S2′ pocket. 
In addition to the changes in the S2 and S2’ pockets of PR20, the shorter side-chain of 
I84V mutation in the S1/S1′ pockets accounts for a net loss of 4 hydrophobic contacts with 2 
compared to those in the wild-type complex. These altered interactions due to mutations in the 
active site of PR20 are expected to enhance affinity for inhibitor 2. 
2.4.4 Comparison of PR20 interactions with inhibitors 1 and 2 
The crystal structure of PR20/2 was compared to PR20/1 (PDB: 3UCB) to understand the 
different inhibition values. The bulky P2 Crn-THF of 2 forms 5 hydrophobic contacts with 
mutations I47V and V32I that cannot occur for bis-THF of 1 in the PR20/1 structure, although 
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the hydrogen bonds are conserved (Figure 4A). The P2′-Cp-Abt group on 2 is also larger than the 
P2′-aniline of 1. Both inhibitors show similar interactions with I47′V and V32′I side-chains, 
however, the extended P2′ group of 2 introduces 10 more hydrophobic contacts with the side-
chains of Asp29′ and Asn30′ (Figure 4B). The thiazole ring of 2 forms a hydrogen bond with the 
Asn30′ amide, while the aniline amide of 1 interacts with the Asn30′ carbonyl. Moreover, the P2′ 
amine in 2 introduces a direct hydrogen bond with Asn30′ side-chain replacing a less favorable 
indirect water-mediated interaction in 1 (Figure 4C).        
Difluorination of the P1-group of 2 enhances its penetration of the cell membrane and 
introduces halogen bonds with wild-type PR267. The P1 bis-FBz forms fluorine bonds with the 
Arg8′ side-chain and the main-chain amide of Ile50 at the flap tip. These halogen bonds bridge 
the S1 pocket and the dimer interface (Figure 4D). Arg8/8′ forms a critical intersubunit ion-pair 
with Asp29′/29 in most PR dimers279. In PR20/1, the larger side-chain of L10F mutation induces 
rotation of the side-chains of Arg8 and Arg8′, thus eliminating the ion-pair with Asp29′/29, 
which has been proposed to increase dissociation of PR20 dimers192. This rotated conformation 
of Arg8 and loss of its intersubunit ion-pair is observed in the S1′ pocket of both PR20/1 and 
PR20/2 structures where the identical P1′-isobutyl group is ~6 Å away from Arg8 (Figure 4E). 
However, in the S1 pocket of PR20/2, the fluorine bond between 2 and Arg8′ acts to overcome 
the effect of the L10′F mutation.   
The P1 bis-FBz group of 2 introduces new hydrophobic contacts with PR20 that cannot 
occur for the smaller P1 of 1. The fluorine atoms make additional contacts with residue Ile50 at 
the flap tip, which may decrease the mobility of the flaps and stabilize the binding of inhibitor 2 
within the expanded active site cavity of PR20.  
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Overall, larger P2 and P2′ moieties for 2 relative to 1 introduce more van der Waals 
contacts with the expanded ligand binding pocket that contribute to better inhibition of PR20, 
although 2 is unable to make contacts with the shorter side-chain of I84V mutation. These 
observations in PR20 are consistent with molecular dynamic calculations comparing van der 
Waals interaction energies between 1 and 2 in PR267. Compared to DRV, compound 2 can form a 
larger number of direct polar interactions with PR20. A fluorine bond between the P1 of 2 and 
Arg8′ restores an inter-subunit ion-pair and may counteract the higher rate of dimer dissociation 
of PR20. The addition of a halogen bond bridge tethering one flap to the protease body stabilizes 
the dynamic flaps. These factors combine to deliver an order of magnitude better inhibition of 
compound 2 over DRV for PR20.    
2.5 Discussion 
Our studies of PR20 mutant address the key challenge of HIV drug resistance 137,191. 
PR20 achieves decreased affinity for inhibitors by synergistic mechanisms of an expanded 
inhibitor-binding cavity, highly dynamic flaps, and accelerated dimer dissociation compared to 
wild-type enzyme. Clinical inhibitor 1, the most potent for wild-type PR (5 pM), exhibits 8,000-
fold worse binding affinity (40 nM) for PR20137. Compound 2, an antiviral inhibitor derived 
from 1, shows 16-fold better Ki than 1 for PR20 (2.5 nM). The larger Crn-THF at P2 and Cp-Abt 
at P2’ groups of 2 introduce additional hydrophobic and polar interactions with the mutated side-
chains of the expanded ligand binding site. The fluorines of P1-bis-FBz of 2 create halogen 
bonds bridging the flap and Arg8′ to stabilize the dynamic flaps and restore an intersubunit ion-
pair that may help to decrease the rate of dimer dissociation.  
Compound 2 successfully realizes the current structure-guided drug design strategy for 
resistant PR. By incorporating larger P2/P2′ groups that fit into the expanded binding pocket and 
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halogen flap interactions, 2 can inhibit PR20 better than the best current clinical PI. Future 
compounds might explore modifications expanding the P1′ group. Furthermore, although these 
larger moieties of 2 help fill the expanded ligand binding pocket of PR20, other mutants exhibit 
few changes in the active site and diminish the potency of PIs through the effects of distal 
clusters of mutations118. In conclusion, antiviral inhibitor 2 is a noteworthy advance in the pursuit 
of potent inhibitors for resistant HIV. 
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Table 2.1 Crystallographic statistics for PR20/GRL-142 
(Values in parentheses are for the highest resolution shell.) 
 PR20/2  
Resolution (Å) 50 - 1.21 
Cell dimensions  
   a (Å) 60.57 
   b (Å) 60.57 
   c (Å) 85.14 
Space group P 61 
Unique Reflections 46,059 
Completeness (%) 99.7 (89.8) 
Redundancy 7.5 (2.3) 
I/σ(I) 21.0 (2.0) 
Rmerge (%) 9.2 (44.8) 
Rwork (%) 15.2 
Rfree (%) 19.0 
Solvent atoms 226 
Average B-factors (Å2)  
   Protein 20.7 
   Inhibitor 13.8 
   Solvent 31.4 
RMSD from ideality  
   Bond lengths (Å) 0.015 
   Bond angles (°) 2.20 
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Figure 2.1: Chemical structures of compounds and PR20 dimer. 
A. Inhibitor 1: darunavir and Inhibitor 2: GRL-142 differ at the P2, P2′, and P1 positions. B. 
Inhibitor 1 (green sticks) bound to the active site of the PR20 dimer (orange cartoon). PR20 
contains 4 mutations in the inhibitor-binding site D30N, V32I, I47V, and I84V (red spheres). 
The L10F mutation (cyan spheres) sits near the dimer interface. Grey spheres indicate other 
mutations. 
53 
  
Figure 2.2:  Inhibitor 2 bound in the active site of drug-resistant PR20.  
A. Fo-Fc omit map (grey mesh) contoured at 2σ for the conformation of 2 (purple sticks) used 
for analysis. B. Polar interactions between 2 and PR20 residues (teal sticks). Dashed lines 
indicate hydrogen bonds (teal) and fluorine bonds (red dashes). New hydrogen bond in PR20/2 is 
orange. 
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Figure 2.3: Interactions of the P2 and P2′ groups of 2 in PR20/2 compared to PR/2  
A. Comparison of P2 Crn-THF group interactions with residues in the S2 pocket of PR20 and 
PR. PR20/2 is colored purple/teal, PR/2 is colored grey. 
B. Comparison of P2′ Cp-Abt group interactions with residues in the S2′ pocket of PR20 and PR. 
Hydrogen bonds and van der Waals contacts are indicated as dashed and dotted lines, 
respectively, in teal for PR20/2 and black for PR/2. Orange dashes indicate hydrogen bonds 
introduced in the PR20/2 structure by mutations D30N and N88D. 
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Figure 2.4: Comparison of interactions in PR20/1 (salmon) and PR20/2 (teal/purple).  
A. Bulky P2 Crn-THF group of 2 creates 5 more van der Waals contacts with PR20 than does the 
bis-THF of 1.  
B. Larger P2′ group on 2 adds van der Waals interactions with Asn30′ and Asp29′ side-chains 
that are absent in PR20/1 structure.  
C. The P2′ Cp-Abt group of 2 forms direct hydrogen bonds with the mutated side-chain of 
D30′N, whereas the aniline group of 1 makes weaker water-mediated hydrogen bonds. Distances 
in Å.  
D. The bis-FBz of 2 makes fluoride bonds (red dashes) with Arg8′ and the tip of the flap at Ile50 
that cannot be formed by the benzyl P1 of 1. Intersubunit ion-pair between Arg8′ and Asp29 in 
PR20/2 is lost in PR20/1 since Arg8′ shifts toward mutated L10F.  
E. The short P1′-isobutyl in 1 and 2 cannot interact with Arg8 in PR20 or wild-type PR 
structures. Arg8 shifts toward mutated L10F in PR20 complexes instead of forming intersubunit 
ion pair observed in PR/2 (grey). 
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3 HIGHLY DRUG RESISTANT HIV-1 PROTEASE MUTANT PRS17 SHOWS 
ENHANCED BINDING TO SUBSTRATE ANALOGS 
Agniswamy J, Kneller DW, Brothers R, Wang Y-F, Harrison RW, Weber IT. (2019) Highly drug 
resistant HIV-1 protease mutant PRS17 shows enhanced binding to substrate analogues. ACS 
Omega. 4(5)8707-8719.   
3.1 Abstract 
We report the structural analysis of highly drug-resistant HIV protease variant PRS17, 
rationally selected by machine learning, in complex with substrate analogs. Crystal structures 
were solved of inhibitor-free inactive PRS17-D25N, wild-type PR/CA-p2 complex and PRS17 in 
complex with substrate analogs, CA-p2 and p2-NC. Peptide analogs p2-NC and CA-p2 exhibit 
inhibition constants of 514 and 22 nM, respectively, for PRS17 or approximately three-fold better 
than for PR. CA-p2 is a better inhibitor of PRS17 than are clinical inhibitors (Ki = 50 – 8390 nM) 
except for (Ki = 11 nM). G48V resistance mutation induces curled flap tips in PR
S17-D25N 
structure. The inner P2 to P2 ' residues of substrate analogs in PRS17 complexes maintain similar 
conformations to those of wild-type complex, while significant conformational changes are 
observed in the peripheral residues P3, P4 of CA-p2 and P3, P4 and P3' of p2-NC. The loss of -
branched side-chain by V82S mutation initiates a shift in 80’s loop and reshapes the S3/S3 
subsite, which enhances substrate binding with new hydrogen bonds and van der Waals 
interactions that are absent in wild-type structures. The steric hindrance caused by G48V 
mutation in the flap of PRS17 contributes to altered binding interactions of P3 Arg, P4 Nle of 
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CA-p2 and P4 and P3' of p2-NC with the addition of new hydrogen bonds and van der Waals 
contacts. The enhanced interaction of PRS17 with substrate analogs agrees with their relative 
inhibition, suggesting this mutant improves substrate binding while decreasing affinity for 
clinical inhibitors. 
3.2 Introduction 
Human Immunodeficiency Virus (HIV) currently infects approximately 36.7 million 
people worldwide. At present, there is no cure for HIV infection or AIDS280.  However, the 
advent of combined antiretroviral therapy (cART) in the late 1990’s using a combination of 
reverse transcriptase and protease inhibitors dramatically suppressed the viral loads and 
increased CD4+ T-cell counts among infected patients281,282. In addition to viral fusion to host 
cell, reverse transcriptase and integrase, HIV protease (PR) is a critical anti-retroviral drug target 
due to its pivotal role in processing of Gag and Gag-Pol polyproteins during viral maturation. 
HIV PR is a homodimeric aspartic protease in which each 99-amino acid monomer contributes 
one of the two catalytic triads (Asp25-Thr26-Gly27) required for catalytic function163. The Gag 
and Gag-pol polyproteins are processed by HIV PR at 10 sites by recognizing specific sequences 
of 7-8 residues at the cleavage site. The substrate residues at the cleavage site are numbered P4-
P3-P2-P1-P1′-P2′-P3′-P4′ with the scissile peptide bond between P1 and P1′ residues. 18O 
exchange mass spectrometry studies have shown that the peptide hydrolysis by HIV PR occurs 
through the formation of a reversible and metastable gem-diol reaction intermediate128. Several 
intermediates in the reaction pathway have been identified in X-ray crystal structures283.  
Inhibition of HIV PR leads to disruption of the virus life cycle at a vital stage125. Currently, there 
are 9 FDA-approved PR inhibitors (PI) that are available for cART. However, due to the rapid 
turnover rate of HIV and the low fidelity of reverse transcriptase (~2 x 10-5 errors/nucleotide per 
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replication cycle), mutations in PR associated with resistance to each of the 9 FDA-approved PIs 
have decreased the efficacy of current treatment options164,284.  Accumulation of 10-20 mutations 
in PR may be required to evolve high levels of resistance165. Patients with multidrug-resistant 
HIV PR were shown to have convergent evolved patterns of accumulated resistance 
mutations285. 
Recently studied HIV PR variant PRS17 has 17 mutations compared to wild-type PR and 
was selected by mean-shift clustering on genotype-phenotype data using a new algorithm for 
predicting drug resistance with a unified encoding of the sequence and 3-D structure202,203. 
PRS17 was predicted to exhibit high-level resistance to six inhibitors: atazanavir, nelfinavir, 
ritonavir, indinavir, lopinavir, and saquinavir, and was subsequently confirmed to have resistance 
to 8 of the 9 currently available clinical inhibitors except for tipranavir which could not be 
measured due to solubility limitations204,206. Structural studies using X-ray crystallography and 
NMR spectroscopy have shown that PRS17 exhibits an open flap conformation in the absence of 
inhibitor in both crystal structure and in solution unlike wild-type PR which is present in the 
closed-flap conformation without the inhibitor in NMR studies118.  In spite of different 
mutational profiles, correlated clusters of mutations in other multidrug-resistant variants of HIV 
PR (PR20 and MDR 769) cause them to also favor an open flap conformation like PRS17 that 
lowers the binding affinity of inhibitors186,192. Altered dynamics of the flap due to mutations is 
likely to increase dissociation rates, and hence, decrease potency of inhibitors286.  Clusters of 
mutations at the hinge loop in PRS17 and PR20 are associated with increased flap dynamics and 
enhanced inhibitor dissociation of the two multidrug-resistant PRs118,192. These mutational 
clusters that function synergistically to produce conformational changes in the PR suggest 
convergent evolution by combinations of single mutations. Variant PRS17 is about 10-fold less 
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efficient than wild-type PR in processing the Gag polyprotein while maintaining the same order 
of substrate cleavage206. PRS17 is also 2-fold less efficient than PR20 in Gag polyprotein 
processing and forms an excellent prototype for structural studies on substrate binding to 
multidrug-resistant PR. 
HIV PR hydrolyzes several sites with markedly different sequences on the nascent 
polyprotein substrate. In order for PR to evolve resistance to multiple drugs while maintaining 
catalytic efficiency for viral replication, mutations that destabilize inhibitor binding must 
combine with mutations that contribute to a new or altered form of substrate binding. This 
perspective shifts the focus of structure-guided drug design from point-based mutations to 
mutation clusters. Studying the mechanism by which multidrug-resistant variants like PRS17 
bind and cleave substrates may elucidate conserved methods of binding across other mutant PRs 
with similar mutational clusters and give insights for improved structure-guided drug design. In 
the current study, we use structural and kinetic studies on PR, PRS17-D25N and PRS17 with 
substrate analogs CA-p2 (R-V-L-r-F-E-A-Nle) and p2-NC (Ace-T-I-Nle-r-Nle-Q-R) to evaluate 
differences in substrate recognition between PRS17 and wild-type PR. The reduced peptide 
analogs are suitable for structural studies with active PR variants since they cannot be 
hydrolyzed. Ace and the isosteric amino-acid norleucine (Nle) in which the sulfur of the Met 
side-chain is replaced by a methylene group were used to simplify synthesis. 
3.3 Materials and methods 
3.3.1 Construction, Expression and purification of PRS17 
Synthetic genes encoding the 99 amino acid protein named PRS17 and its active site 
mutant PRS17-D25N (DNA2.0, Menlo Park, CA) were cloned in pJ414 vector flanked by Nde1 
and BamH1 sites, and transformed into E.coli BL-21 (DE3; Stratagene). DNA sequencing and 
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electrospray ionization mass spectrometry were used to verify the recombinant construct. Protein 
expression, purification and refolding were carried out as described previously287,288. In brief, 
cells were expressed in Luria-Bertani medium and induced with 2mM IPTG. The harvested cells 
were lysed by addition of lysozyme (100 µg mL-1) and sonication at 4°C. The pelleted inclusion 
bodies were washed and solubilized in 50 mM Tris-HCL, pH 8.0, 8 M guanidine hydrochloride, 
5 mM EDTA and 10 mM DTT. The protein was purified over a Superdex-75 column (HiLoad 
2.6 cm x 60 cm, GE HealthCare) under denaturing conditions. The peak fractions were further 
purified by reverse-phase HPLC on SOURCE 15RPC ST 4.6/100 column using AKTA pure 
chromatography system (GE HealthCare). The purified protein was refolded by extensive 
dialysis against 30 mM formic acid and concentrated to the desired level using Amicon Ultra 
concentrators. 
3.3.2 Kinetic inhibition measurements 
Kinetic inhibition values (Ki) of p2-NC and CA-p2 for PRS17 were measured using a 
spectroscopic FRET substrate analog of the p2-NC site (H-2992 – BACHEM, Bubendorf, 
Switzerland). The peptide sequences of the two substrate analogs are R-V-L-r-F-E-A-Nle for 
CA-p2 and Ace-T-I-Nle-r-Nle-Q-R p2-NC.  Enzyme kinetic parameters kcat and Km were 
determined for PRS17 using Michaelis-Menton analysis at 14-180 µM substrate concentration 
[S]. The kcat and Km are 69.7 ±14.4 min
-1 and 143 ± 33.0 µM, respectively. The kcat/Km for 
PRS17 of 0.49 ± 0.05 min-1 µM-1 is comparable to previously reported values using a different 
method (0.55 min-1 µM-1)206.  Reactions were performed in a total volume of 100 µL at 37°C in 
50 mM MES pH 5.6, 200 mM sodium chloride, 0.5 mM EDTA, and 2.5% glycerol. Enzyme 
concentration [E] was 180-370 nM as measured by active site titration with APV. Inhibition 
assays used 60 µM [S]. The rate of substrate cleavage under a range of substrate analog 
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concentrations was measured continuously for 5 minutes by excitation at 340 nm and emission at 
420 nm using a POLARstar OPTIMA microplate reader. The Ki value was determined using the 
equation Ki = (IC50 − [E]/2)/(1 + [S]/Km). IC50 was determined from dose-response curves. Km 
values of FRET substrate for PRS17 were determined from Michaelis-Menton analysis at 14-180 
µM [S]. All calculations were fitted using Sigmaplot 12.0 (Systat Software Inc., San Jose, CA, 
USA). 
3.3.3 Crystallization 
PRS17 was complexed with substrate analogs CA-p2 and p2-NC dissolved in DMSO at 
1:5 molar ratio and incubated on ice for 30 minutes. The complex was centrifuged at 10,000 rpm 
for 5 minutes and the supernatant was used for crystallization. The crystallization trials were 
performed at room temperature with hanging drop vapor diffusion technique. The hanging drop 
in all crystallization trials was set up with 1 µL of protein solution (5mg/mL) and 1 µL of 
reservoir solution. Crystals of inhibitor-free PRS17-D25N were obtained from 1.95M sodium 
chloride and 0.1M Bis-Tris pH 7.5. Crystals of PRS17/CA-p2 were grown from reservoir 
solution containing 2.1M sodium chloride and 0.1M HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid) at pH 7.6. The PRS17 crystals in complex with substrate analog 
p2-NC were obtained in two different space groups P41 and P61. The well solution used for 
growing PRS17-P41/p2-NC crystals was 29.5% PEG 4000, 0.2M ammonium acetate and 0.1M 
sodium acetate buffer at pH 4.6. The PRS17-P61/p2-NC crystals were grown from 35% 
TacsimateTM, pH 7.0 (Hampton Research Corp., Aliso Viejo, CA). TacsimateTM contains 1.83 M 
malonic acid, 0.25 M ammonium citrate tribasic, 0.12 M succinic acid, 0.3 M DL-malic acid, 0.4 
M sodium acetate trihydrate, 0.5 M sodium formate, and 0.16 M ammonium tartrate dibasic. 
Crystals of wild-type PR/CA-p2 were obtained from 1M sodium chloride and 0.1M sodium 
62 
acetate at pH 4.8. The crystals were cryo-cooled with cryoprotectant containing the respective 
mother liquor together with 30% glycerol. 
3.3.4 X-ray data collection and structure determination 
X-ray diffraction data were collected at 100 K on beamline 22-ID of the Southeast 
Regional Collaborative Access Team (SER-CAT) at the Advanced Photon Source, Argonne 
National Laboratory. The data were integrated and scaled with HKL2000271. The crystal 
structures of PRS17 active site mutant PRS17-D25N and the substrate analog complexes, 
PR/CA-p2, PRS17/CA-p2, PRS17-P41/p2-NC and PRS17-P61/p2-NC were solved by molecular 
replacement using PHASER289,290. The previously solved crystal structure of active PRS17 
(5T2E)118 was used as the starting model for PRS17 active-site mutant PRS17-D25N. For 
PR/CA-p2 substrate analog complex, the crystal structure of PR/p2-NC24 (2AOD) was used as 
the starting model. For PRS17/CA-p2 substrate analog complex, the crystal structure of PRS17 
complex with darunavir (DRV)118 (5T2Z) was used as initial model. Crystal structure of multiple 
mutants V6 in complex with indinavir (1SGU)291 was used to solve both PRS17/p2-NC 
complexes. The PR/CA-p2 complex was refined with SHELX-1997292. The PRS17/CA-p2 
complex was refined using REFMAC293 while the PRS17-D25N and PRS17/p2-NC complexes 
were initially refined by SHELX-2014294 and switched to REFMAC during later cycles of 
refinement. COOT274 was used for most model building except O295 was applied for PR/CA-p2. 
In PRS17/p2-NC complexes, mutations were added to the model based on the primary sequence 
and difference density maps. The substrate analogs were fitted into unambiguous electron 
density in the four complex structures. Solvent molecules were inserted at stereo chemically 
reasonable positions using 2Fo-Fc and Fo-Fc maps at 1 and 3 sigma levels, respectively. 
Molecular figures were prepared with PyMOL (http://www.pymol.org). 
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3.3.5 Accession codes 
Coordinates and structure factors for the crystal structures PR/CA-p2 (6O48), PRS17-
D25N (6O54), PRS17/CA-p2 (6O5X), PRS17-P41/p2-NC (6O57) and PRS17-P61/p2-NC 
(6O5A) have been deposited in the Protein Data Bank. 
3.4 Results  
3.4.1 Substrate analog inhibition of PRS17 
Gag cleavage sites p2-NC and CA-p2 are the first and last proteolytic sites to be 
processed in the Gag precursor83. Mutations accumulating near the p2-NC cleavage site have 
been shown to improve processing fitness of a highly-mutated HIV PR sequence isolated from a 
patient failing antiviral therapy153. Reduced peptide analogs corresponding to the amino acid 
sequence of Gag cleavage sites act as competitive inhibitors of HIV PR catalytic 
activity170,296,297. In the present study, reduced peptide analogs for p2-NC and CA-p2 cleavage 
sites inhibited proteolytic activity of the drug resistant HIV-1 PR mutant PRS17. The kcat and Km 
values measured for PRS17 are 69.7 ±14.4 min-1 and 143 ± 33.0 µM, respectively. The kcat/Km of 
PRS17 is 0.49 ± 0.05 min-1 µM-1. Inhibition constants (Ki) measured for PRS17 were 514 nM for 
p2-NC and 22 nM for CA-p2. The inhibition constants (Ki) of substrate analogs for PRS17 are 
compared with values for PR and PRV82A determined previously in Table 3.1. Interestingly, 
reduced peptide analog CA-p2 displays better inhibition values for PRS17 than those of clinical 
inhibitors (Ki = 50 – 8390 nM) except for amprenavir (APV) (Ki = 11 nM) as measured by 
isothermal titration calorimetry206. CA-p2 and p2-NC substrate analogs are 3.4 and 4.2-fold 
better inhibitors for PRS17, respectively, when compared to PR whose Ki values are 75 nM and 
2.17 µM. The major effect appears to be mutation to a smaller side-chain at Val82, since PR 
bearing single mutation V82A (PRV82A) displays almost identical inhibition kinetics for CA-p2 
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(Ki = 24 nM) and p2-NC (Ki = 530 nM) as those measured for PRS17
170. PRS17 has a serine at 
this position, which is the only mutation in the active site cavity apart from those in flaps. 
3.4.2 Overall structure 
Crystal structures of inhibitor-free PRS17-D25N and wild-type PR in complex with CA-
p2 substrate analog were determined in the P3221 and P21212 space groups at 1.21 and 1.46 Å 
resolution, respectively. PRS17 complex with CA-p2 crystallized in the monoclinic space group 
P21 and was refined to 1.7 Å, while PRS17 in complex with p2-NC was determined in two 
different space groups P41 and P61 at 1.71 and 1.67 Å resolution, respectively. The five 
structures were refined to R-factors of 14.8 – 19.8% as shown in the crystallographic statistics of 
Table 3.2. The inhibitor-free PRS17-D25N structure has one monomer in the asymmetric unit 
with residues numbered 1-99, while PR/CA-p2, PRS17-P41/p2-NC and PRS17-P61/p2-NC 
complexes contain a dimer of subunits numbered 1-99 and 1′-99′ in the asymmetric unit. 
PRS17/CA-p2 complex has two dimers per asymmetric unit. The substrate analogs bound at the 
active site in a single conformation in all PR and PRS17 complexes. All 17 mutations in the 
PRS17 (Fig 3.1A) and substrate analogs were unambiguously modeled in the electron density 
maps (Fig 3.1B and C).  The reorganization of the hinge loop by mutations E35D, M36I and 
S37D that breaks the ion pair anchoring the flaps and thereby increases the flap flexibility as 
described in the previously determined complex of PRS17 with darunavir (DRV)118 is also 
observed in the current substrate analog complexes. 
3.4.3 Curling of flaps in PRS17-D25N  
The current crystal structure of PRS17-D25N at 1.21 Å is the highest resolution HIV PR 
structure in the open conformation available to date. Comparison of inhibitor-free PRS17-D25N 
with the wild-type PR open form without inhibitor (2PC0) shows that the two structures 
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superpose with RMSD of 1.4 Å for the 99 topologically equivalent Cα atoms. The maximum 
deviation of 6.9 Å between the two structures occurs at Ile50 at the tip of the flap. Similar to 
wild-type PR, the flaps of PRS17-D25N are in an open conformation. The three mutations 
M46L, G48V and I54V in PRS17 flaps act to curl the tip of flaps (Figure 3.2A). The twist in the 
flap starts at G48V of PRS17-D25N with a drastic change in φ angle by ~172° in comparison 
with Gly48 of wild-type PR. The introduction of Val48 side-chain in PRS17-D25N results in 
~1.1 Å shift of Phe53 side-chain’s benzene ring when compared to that of wild-type PR. This 
shift results in loss of van der Waals contacts observed in wild-type PR between the side-chain of 
Phe53 and Gly48. In addition to the shift in Phe53, mutation of Met46 to shorter Leu46 in 
PRS17-D25N also eliminates van der Waals contacts observed in wild-type PR between Phe53 
and Met46. This curling of flap tips propagates from G48V up to Gly52 in PRS17-D25N. As a 
result, the tip of the flap of PRS17-D25N moves ~ 4.4 Å closer to 80’s loop as measured by the 
distance between the Cα atoms of Ile50 and Thr80. This distance is 14.5 Å for the wild-type PR, 
while it is 10.1 Å for the PRS17-D25N structure. The residues in 80’s loop play an important 
role in the binding of both substrate and inhibitors to PR. Conformational changes and shifts in 
the 80’s loop due to resistant mutations can eliminate interactions with inhibitors in both single 
mutants of PR and variants with multiple mutations163,187,192. On the other hand, the flap curling 
also increases by ~1.4 Å the distance between the flap tip of PRS17-D25N and active site, since 
the distance between the Cα atoms of Asp25 and Ile50 increased from 17.6 Å in the wild-type 
structure to 19.0 Å in PRS17-D25N. Nearly identical curled-flap conformation was seen in the 
recently reported inhibitor-free PRS17 structure118. The overall structure of PRS17-D25N is very 
similar to the inhibitor-free PRS17 structure with a RMSD of 0.18 Å for 99 equivalent Cα atoms. 
The maximum deviation between the two structures occurs for residue Ile50 at the flap tip with a 
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RMSD of 1.1 Å. Similar to PRS17-D25N, the flap curling in PRS17 starts with ~176° change in 
φ angle of G48V and ends at Gly52. However, the peptide bond between Ile50 and Gly51 is 
flipped in PRS17 structure in comparison to PRS17-D25N (Figure 3.2B). This flipped peptide 
bond enables residue Ile50 at the flap tip of PRS17 to move closer to the 80’s loop residue Thr81 
(~8.8 Å) than PRS17-D25N (10.1 Å), while the distance between catalytic Asp25/Asn25 and the 
flap tip Ile50 remains more or less same between the two structures (18.7 Å for PRS17 and 19.0 
Å  for PRS17-D25N). Both conformations of peptide bond between Ile50 and Gly51 are 
observed in other PR structures, which suggest it can exist in either conformation. Also, PR with 
individual mutations of M46L, G48V and I54V in the flaps showed worse inhibition constants 
(Ki) for DRV and saquinavir relative to wild-type PR
298,299. Thus, identical curling of flaps in two 
independently determined structures of PRS17-D25N and PRS17 strongly implies that the 
conformational changes are due to the three mutations M46L, G48V and I54V in the flaps of 
PRS17 and contribute to the altered kinetic characteristics of PRS17. 
3.4.4 PRS17 recognition of the P2, P1′ - P3′ groups of CA-p2 is unaffected by the resistance 
mutations 
The PRS17/CA-p2 structure has 2 PR dimers in the asymmetric unit. The two dimers 
agree well and can be superposed with RMSD of 0.78 Å for the 198 canonically equivalent Cα 
atoms. Comparison of the two dimers in PRS17/CA-p2 structure with the wild-type PR/CA-p2 
complex with one dimer in the asymmetric unit shows RMSD of 1.05 and 0.71 Å, respectively, 
for each dimer. The maximum deviation of 4.4 Å occurs between residues Glu35′ of PR/CA-p2 
and PRS17/CA-p2 in dimer 1, while 4.3 Å deviation is observed between Glu35 positions in 
dimer 2. PR forms a series of hydrogen bond interactions with main-chain amide and carbonyl of 
the substrate that are important for recognition of peptides170. Similar hydrogen bonds between 
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the main-chains of PR and substrate analog were observed in both PR/CA-p2 and PRS17/CA-p2 
complexes (Figure 3.3A), except for a new longer hydrogen bond between the main-chain amide 
of P4′ Nle and the side-chain of Asp29′ or Asp30′ in PRS17/CA-p2 complex which will be 
discussed in a later section. The conformations of P2 Val, P1′ Phe, P2′ Glu and P3′ Ala of CA-p2 
and their interactions with the wild-type PR and PRS17 are similar in both complexes. However, 
conformational differences in P1 Leu, P3 Arg and P4′ Nle of CA-p2 and variations in their 
interaction with PR residues are observed between PR/CA-p2 and PRS17/CA-p2 complexes. 
The P1 Leu of PR/CA-p2 forms van der Waals interactions with -branched aliphatic 
side-chain of Val82′. In PRS17/CA-p2 complex, Val82 is mutated to polar Ser82 which alters the 
size of the S1 pocket where Pl Leu binds. The Pl Leu side-chain in PRS17/CA-p2 is rotated by 
~46° about the χ2 angle in comparison to its conformation in the wild-type complex thus 
enabling P1 Leu to retain its van der Waals interaction with the side-chain of V82′S in PRS17 
(Figure 3.3B). The conformational change in the side-chain of P1 Leu also facilitates retention of 
van der Waals contacts with Leu23′, Gly27, Ile50, Pro81′ and Ile84′ observed in PR/CA-p2 
complex (Figure 3.3B). The P1 Leu of CA-p2 in the second dimer of PRS17/CA-p2 complex 
exhibits an identical conformation change with ~46° rotation about χ 2 angle and retention of van 
der Waals contact with V82′S side-chain, which further confirms that the observed change in P1 
Leu of CA-p2 occurs in response to V82′S mutation in PRS17. 
3.4.5 Altered recognition of CA-p2 P3 Arg modulated by V82S mutation 
The P3 Arg main-chain of PR/CA-p2 is fixed in position by the hydrogen bond between 
the N-terminal group of P3 and the side-chain of Asp29 and a second hydrogen bond between 
the main-chain carbonyl of P3 Arg and the main-chain amide of Asp29. These two hydrogen 
bonds between Asp29 and the main-chain of P3 Arg are also present in PRS17/CA-p2 complex 
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(Figure 3.4A). The side-chain of P3 Arg in the wild-type complex extends over the Gly48 in the 
first strand of flap and forms van der Waals contacts with the Phe53 side-chain in the second 
strand of the flap. In PRS17, the Val side-chain of G48V mutation produces steric hindrance and 
prevents formation of the interaction between Phe53 and P3 Arg observed in wild-type PR 
complex. The tip of Phe53 benzene ring in PRS17/CA-p2 moves away by more than 2 Å in 
comparison to wild-type complex. In PRS17/CA-p2 complex, P3 Arg is observed in three 
different conformations. Conformation 1 is in dimer 1 of PRS17/CA-p2 complex, while 
conformations 2 and 3 of P3 Arg are present as alternate conformations of 0.5 occupancy each in 
the dimer 2 of PRS17/CA-p2 complex. Due to steric hindrance caused by G48V mutation, all 
three conformations of the side-chain of P3 Arg in PRS17/CA-p2 dimers swing away from 
Val48 and interact with Arg8′. The inter-subunit ion pair formed by Arg8′ and Asp29 is critical 
for the dimer stability of HIV PR92. PRS17 utilizes both residues involved in this conserved ion 
pair to recognize and position P3 residue of CA-p2 substrate. 
The new conformation of P3 Arg forms additional van der Waals contacts with Arg8′, 
G48V, Pro81′ and Ser82′ in PRS17 relative to those observed in the wild-type complex (Figure 
3.4A). Also, the new orientation of P3 Arg guanidine head forms water-mediated hydrogen 
bonds with the hydroxyl side-chain of Ser82′, which stabilizes the conformation of P3 Arg. 
Further, the guanidine head of P3 Arg in PRS17/CA-p2 forms a double water-mediated hydrogen 
bond with the carbonyl oxygen of catalytic-triad residue Gly27 and Asp29. These internal 
structural waters are highly conserved in most HIV PR structures including the wild-type 
PR/CA-p2 complex. Similar interactions are also observed for the conformation 2 and 3 of P3 
Arg in the second dimer of PRS17/CA-p2 (Figure 3.4B). In conformation 2, the guanidine of P3 
Arg forms stacking interaction with Arg8′ (Figure 3.4C) while the guanidine of P3 Arg in 
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conformation 3 forms van der Waals interaction with Arg8′ and hydrogen bond interaction with 
the main-chain carbonyl oxygen of Pro81′ (Figure 3.4D). The P3 Arg conformation 3 in dimer 2 
forms fewer van der Waals contacts to Arg8′ than seen for conformation 1 in dimer 1. The 
guanidine head of P3 Arg in conformation 2 is buried deep in the pocket and forms additional 
van der Waals contacts with Leu23′ that are not present in conformations 1 or 3. This 
conformation is further held in place by a single water-mediated hydrogen bond between P3 Arg 
guanidine head and Asp29 as well as another one to the main-chain carbonyl of catalytic triad 
residue Gly27 of PRS17. In contrast, conformation 3 forms double water-mediated hydrogen 
bonds with Gly27 and Asp29.  The guanidine head of both conformation 2 and 3 of P3 Arg in 
dimer 2 has a water-mediated hydrogen bond to the hydroxyl of Ser82′ which further anchors P3 
Arg of substrate analog. The V82′S mutation in PRS17 facilitates the new conformation of P3 
Arg side-chain, since Val82′ in the wild-type complex would sterically interfere with P3 Arg in 
this location. Mutations of Val82 to Ala, Thr, Phe, Ile, Ser and Leu are associated with resistance 
to clinical HIV PR inhibitors164,300. Similar to V82S mutation in PRS17, V82′A mutation is also 
expected to expand the binding site for P3 Arg, but other larger and β-branched mutations may 
block the access to this site. The co-occurrence of flap mutations like G48V that block P3 
substrate-binding site and large substitutions at residue 82 like V82F, V82L and V82I that block 
the alternate P3 binding site are expected to be detrimental to PR activity. In the previously 
solved crystal structure of PRV82A/CA-p2, the substrate analog is in two alternate 
conformations related by 180° with 0.65/0.35 occupancies as opposed to a single conformation 
in the current PR and PRS17 complexes. The major conformation of P3 Arg in the PRV82A/CA-
p2 complex forms van der Waals contact with Phe53 in the second strand of the flaps similar to 
PR/CA-p2 complex while the carbonyl of P4  Nle of the minor conformation related by 180° 
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occupies the P3 Arg site observed in the PRS17/CA-p2 complex (Figure 3.4E). Similar to V82S, 
V82A mutation opens up the S3 site for substrate recognition. Thus, in PRS17/CA-p2 complex, 
the G48V flap mutation in conjunction with the V82S mutation facilitates binding of the side-
chain of P3 Arg in the new site. The effect of Val82 mutation appears to be two-fold; it alters the 
resistance profile of PR inhibitors and regulates the access to Arg8/8′ in the recognition of 
substrate P3 residue in response to resistance flap mutations like G48V that hinder substrate 
recognition. 
3.4.6 Effects of G48′V mutation on binding of CA-p2 P4′ Nle to Leu76′ hydrophobic pocket 
Comparison of PR and PRS17 complexes with CA-p2 reveals significant differences in 
the binding of P4′ Nle. In wild-type PR/CA-p2 complex, the terminal P5′ NH2 group forms a 
hydrogen bond interaction with the main-chain carbonyl of Leu46 and van der Waals 
interactions with Phe53 in the second strand of the flap (Figure 3.4F). However, in the mutant 
PRS17/CA-p2 complex, the introduction of G48V mutation causes the Phe53 side-chain to rotate 
out by more than 140° in comparison to wild-type complex. The G48V mutation further 
contributes to more than 1.5 Å shift in the position of terminal P5′ NH2 which losses van der 
Waals contact with Phe53 but retains the hydrogen bond with the carbonyl of Leu46. The main-
chain amide of P4′ Nle is moved by ~0.8 Å in the PRS17/CA-p2 complex in comparison to the 
wild-type complex, which results in a new long hydrogen bond (~3.5 Å vs ~4.1 Å in the PR/CA-
p2 complex) between the main-chain amide of P4′ Nle and the side-chain of Asp29′ in dimer 1. 
P4′ Nle amide in dimer 2 forms a water-mediated hydrogen bond with Asp29′ and a new long 
hydrogen bond with the side-chain of Asp30′ (~3.5 Å vs ~3.8 Å). The Cα atom of P4′ Nle is also 
shifted by ~1.2 and 0.5 Å in comparison to its position in PR/CA-p2 in dimer 1 and 2 
respectively. Along with the shift in the main-chain atoms, the side-chain of P4′ Nle in dimer1 
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swings into the hydrophobic pocket around Leu76′ and forms a hydrophobic interaction with the 
side-chain of Leu76′.  The side-chain of Lys45′, which occupies this pocket and has van der 
Waals contacts with Asp30′ in the wild-type PR/CA-p2 structure, swings away to form a van der 
Waals interaction with the Gln58′ side-chain in PRS17/CA-p2 complex, thereby enabling P4′ 
Nle of CA-p2 to interact with Leu76′. P4′ Nle bound in this pocket also forms van der Waals 
interactions with Asp30′, Lys45′ and Gln58′ in the mutant. In contrast, the P4′ Nle side-chain in 
wild-type complex shows van der Waals contact with only one residue, Lys45′. The P4′ Nle side 
chain in the second dimer of PRS17/CA-p2 also binds in the same pocket with similar 
interactions due to the G48′V flap mutation in PRS17. Thus, the G48′V mutation in the flap and 
the altered conformation of Phe53′ in PRS17/CA-p2 complex induce a shift in P4′ Nle side-chain 
away from the flaps to form a new hydrogen bond with Asp29′ or Asp30′. Further, the side-chain 
of P4′ Nle in the new orientation binds in the hydrophobic pocket near Leu76′ with added van 
der Waals contacts. Overall, this new arrangement in the mutant confers favorable interactions 
with P4′ Nle. 
3.4.7 Mutation V82S mediates enhanced binding of P3′ Arg in p2-NC 
PRS17 in complex with p2-NC was crystallized in two different space groups P41 and 
P61 and refined to resolutions of 1.71 and 1.67 Å, respectively. Both structures have one PRS17 
dimer per asymmetric unit and a single conformation of substrate analog bound at the active site 
cavity. The two structures are very similar with RMSD of 0.5 Å for 198 equivalent Cα atoms. 
The previously solved PR/p2-NC complex can be superposed with the PRS17-P41/p2-NC and 
PRS17-P61/p2-NC complexes with RMSD values of 0.99 and 0.96 Å, respectively, for the 198 
equivalent Cα atoms. Despite their different space groups, both structures exhibit a maximum 
deviation of more than 4.3 Å at the same residue, Asp35, in comparison to wild-type structure. 
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The conformation of P2, P1, P1′, P2′ and P4′ residues of p2-NC and their interactions with 
PRS17 residues are similar for PRS17/p2-NC complexes in the two space groups and PR/p2-NC. 
However, noticeable differences occur at residues P3′, P3 and P4 of PRS17-P41/p2-NC and 
PRS17-P61/p2-NC in comparison to PR/p2-NC. 
Unlike the P3 Arg of PR/CA-p2 complex, the P3′ Arg of PR/p2-NC binds in the space 
between Arg8 and Val82 (Figure 3.5A). The side-chain of P3′ Arg forms van der Waals contacts 
with Arg8 and the CD2 side-chain atom of Val82.  In both PRS17-P41/p2-NC and PRS17-
P61/p2-NC complexes, the P3′ Arg binds in the same pocket albeit the guanidine head of P3′ Arg 
is tilted towards V82S mutation due to the lack of a β-branched C atom in residue 82.  The N2 
atom of the guanidine head of P3′ Arg in PRS17 complexes is shifted by 1.0 Å (PRS17-P41/p2-
NC) and 1.2 Å (PRS17-P61/p2-NC) towards V82S in comparison to the PR/p2-NC complex. 
The loss of β-branched side-chain in V82S mutation results in a significant shift of 80’s loop 
residues towards Arg8 in PRS17 complexes. The Cα atoms of residues Thr80, Pro81 and V82S 
are shifted by 1.1, 1.3, 0.7 Å, respectively, for the PRS17-P41/p2-NC complex and 1.3, 1.4, 0.6 
Å for the PRS17-P61/p2-NC complex from the corresponding Cα atoms in PR/p2-NC complex 
(Figure 3.5A). This shift contracts the binding pocket for P3′ Arg of p2-NC by 1.3 Å and 1.4 Å, 
as measured by the distance between the guanidine head Nη1 of Arg8 and the Cα atom of Pro81, 
in PRS17-P41/p2-NC and PRS17-P61/p2-NC in comparison to the wild-type complex. This 
narrowing of the pocket results in enhanced binding of P3′ Arg as it is able to form a new 
hydrogen bond interaction with the main-chain carbonyl of Pro81 in addition to van der Waals 
interactions with the side-chain of Pro81 in PRS17/p2-NC complexes. In contrast, P3′ Arg in the 
wild-type PR/p2-NC complex has no interaction with Pro81. Both mutant PRS17/p2-NC 
complexes retain the extensive van der Waals contacts between the Arg8 of PRS17 and P3′ Arg 
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of substrate analog seen in wild-type complex. Similar shifting of 80’s loop residues is also 
observed in P3 pocket of both dimers of PRS17/CA-p2 complex in comparison to wild-type 
structure, although the shifts are reduced by half ranging from 0.3 – 0.5 Å, likely due to the two 
alternate conformations of P3 Arg bound in this pocket. Thus, analysis of the three PRS17 
substrate analog complexes indicates that the loss of β-branched side-chain by V82S mutation 
initiates shifting of 80’s loop and reshapes the S3/S3’ subsite for enhanced binding and 
interactions with P3/P3’. 
3.4.8 G48V mutation of PRS17 results in altered binding position of P3 and P4 residues of 
p2-NC and addition of two new hydrogen bonds  
The P3 Thr in both PRS17-P41/p2-NC and PRS17-P61/p2-NC complexes exhibits 
significant structural changes in comparison to wild-type complex. The p2-NC main-chain 
carbonyl oxygen of P3 Thr occupies identical positions in all three structures. The hydrogen 
bond observed between the P3 carbonyl and the main-chain amide of Asp29 in PR/p2-NC 
complex as well as the conserved water-mediated hydrogen bonds between the P3 carbonyl and 
Gly27 and Asp29 are preserved in both PRS17/p2-NC complexes.  However, the larger G48V 
mutation in PRS17 complexes induces shifts in P3 Thr Cα and Cβ atoms by ~ 0.7 Å and 1.8 Å in 
comparison to their corresponding positions in PR/p2-NC complex (Figure 3.5B). In this new 
conformation, the P3 Thr side-chain forms several van der Waals contacts with the side-chains of 
G48V mutation and Arg8′ in PRS17 complexes. It also forms a hydrogen bond interaction with 
Arg8′ side-chain in both the complexes. In contrast, P3 Thr side-chain in wild-type PR/p2-NC 
complex forms a lone van der Waals contact with Arg8′ side-chain, but no hydrogen bonds. In 
comparison to the wild-type complex, the main-chain amide nitrogen of P3 Thr in both 
PRS17/p2-NC complexes is rotated about ~160° along the main-chain Cα-C bond. This results in 
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a shift of the amide nitrogen of P3 Thr in both mutant complexes by ~2.8 Å from the 
corresponding position in PR/p2-NC complex. The amide nitrogen of P3 Thr forms a hydrogen 
bond interaction with the carbonyl oxygen of Gly48 in wild-type PR/p2-NC complex, while it 
interacts with the side-chain of Asp29 in both PRS17/p2-NC complexes.  
 The terminal P4 Ace residue of p2-NC exhibits the maximum deviations among the 
substrate analog residues in both PRS17 complexes in comparison to PR/p2-NC. The P4 residue 
in the PRS17 cannot occupy the same pocket as in the wild-type structure due to steric hindrance 
from G48V mutation and the loss of interaction with Val82′ as a result of V82′S mutation. The 
P4 Cα is shifted by ~4.6 Å in both complexes from its position in the wild-type complex. Due to 
G48V mutation inducing ~160° of rotation along the Cα-C bond of P3 residue, the P4 Ace 
residue occupies a different binding pocket in PRS17 complexes to that observed in the wild-
type structure. The P4 residue in wild-type PR/p2-NC complex forms van der Waals contacts 
with Gly48, Gly49, Pro81 and Val82. In contrast, the P4 residue in PRS17/p2-NC complexes has 
van der Waals contacts with a different set of residues: Val48, Asp29, Asp30, Lys45, and Ile47.  
In addition, the main-chain carbonyl oxygen of the P4 residue in PRS17 complexes forms new 
hydrogen bond interaction with the main-chain amide of Val48. Thus, despite large shifts in P3 
and P4 residues induced by the G48V mutation, PRS17 accommodates the substrate residues in 
alternate sites and gains two hydrogen bond interactions. The new hydrogen bonds observed in 
the PRS17/p2-NC complexes likely contribute to the improved p2-NC substrate analog 
inhibition constant observed for PRS17 compared to PR. 
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3.4.9 PRS17 binds substrate analogs CA-p2, p2-NC and inhibitor DRV without drastic 
change in PR conformation around the active site 
The two dimers of the PRS17/CA-p2 complex together with the PRS17-P41/p2-NC and 
PRS17-P61/p2-NC structures can be superposed with PRS17/DRV complex with an RMSD of 
0.4 to 0.7 Å. No dramatic changes are observed in the conformation of residues around the active 
site catalytic triad and the binding of substrate analogs and inhibitor (Figure 3.5C). Most of the 
conformational changes are seen in the flap residues. The serine side-chain of V82S mutation in 
both monomers of PRS17/DRV has two alternate conformations mimicking the two β-branches 
of valine, while in the substrate analog complexes it has a single conformation that points away 
from Arg8 to accommodate the substrate residues. Side-chain rotamer changes are observed in 
Phe53 and in mutated side-chains of Leu46 and Val48 in complexes with DRV and the two 
substrate analogs. In addition, shifts are observed for flap residues.  A shift of 0.8 Å in M46L is 
observed in PRS17/CA-p2 in comparison to complex with DRV. Similarly, Val48 of PRS17 
shifts by 0.6 Å when bound to p2-NC analog in comparison to its position in the complex with 
DRV. Flap mutations M46L, G48V and I54V in PRS17 are implicated in the curling of flaps 
observed in the inhibitor-free structure118.  In PRS17/DRV complex, M46L and G48V mutations 
are shown to synergistically alter the conformation of Phe53 by steric hindrance underling the 
relationship between the three residues118. Through changes in the flap strands including the 
position of M46L or G48V in combination with the change in rotamer for side-chains of Leu46, 
Val48 and Phe53, PRS17 binds substrate analogs as well as it binds DRV (Ki = 50 nM). The 
larger side chain of the G48V mutation in the S2 pocket may play an important role in the better 
inhibition constant (Ki = 11 nM) of APV for PRS17. Thermodynamic integration and MM-PBSA 
studies have shown that the larger side-chain introduced by G48V mutation strengthens van der 
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Waals interactions with APV30. However, G48V together with M46L also alters the 
conformation of other flap residues like Phe53 as seen in PRS17/DRV complex118 which may 
affect the inhibitor binding. Thus, minimal structural changes enable highly drug-resistant 
PRS17 to bind substrate analogs with similar affinity as for DRV, and better than for the other 
clinical inhibitors, contributing to both viral fitness and drug resistance. 
3.5 Discussion 
Our studies on PRS17 demonstrate the value of using machine learning on genotype-
phenotype data to select informative mutants for further analysis. Among the 17 mutations in 
PRS17, G48V and V82S play critical roles in binding of CA-p2 and p2-NC substrate analogs. 
The active site cavity around Val82 is important for the binding of PR substrates as well as 
clinical inhibitors. Drug-resistant mutations of Val82 are reported for all clinical PR inhibitors 
except for DRV164. The side-chains of mutations vary in size from the smaller V82A to bulkier 
V82F in addition to V82S, V82T, V82L and V82I that are in between164. V82A is one of the 
earlier PR mutations to occur at the active site among patients undergoing antiviral therapy301 
and has been the best studied mutation at position 82. Kinetic studies have shown that PR 
bearing the single V82A mutation has significantly worse affinity for PR inhibitors indinavir, 
nelfinavir, ritonavir and DRV, while smaller effects were seen for cleavage of PR substrate180,302–
304. Structural studies on V82A mutant in complexes with nelfinavir, indinavir, ritonavir, DRV 
and saquinavir all reveal a small shift in residues to accommodate the inhibitor, explaining the 
cross-resistance profile of this mutation to all PR inhibitors163,305. Resistance mutations like 
V82A at the active site of HIV PR interfere with the binding of drugs, however, replication of 
the virus requires successful binding and hydrolysis of Gag and Gag-Pol substrates by resistant 
PR variants. Crystal structures of inactivated PR with active site D25N and V82A mutations in 
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complex with substrates CA-p2, p1-p6 and MA-CA show high structural similarity with 
inactivated PR-D25N/substrate complexes306 which indicates that V82A mutation in conjunction 
with active site D25N does not affect substrate binding. However, mutations in the Gag substrate 
cleavage sites can co-evolve with resistance-associated mutations in HIV PR or mutations that 
alter the fitness of HIV PR154,307,308.  NC-p1 cleavage site, which is the rate limiting step in Gag 
polyprotein processing309, has been reported to co-evolve with Ala to Val mutation at the P2 
position of the substrate in response to V82A resistant mutation277,307,310.  
 Mutations in the flap region also alter the PR susceptibility to inhibitors. In particular, 
flap mutation G48V confers a high level of resistance to saquinavir205. G48V mutation is also 
selected by PR inhibitors atazanavir, indinavir, lopinavir and nelfinavir205,311,312. G48M has a 
similar resistance profile as G48V205. Less prevalent resistance mutations G48A/S/T/Q are less 
well studied and their clinical significance is not fully understood313. Most of the Gly48 
mutations occur in viruses with multiple PI-resistant sequences313 like PRS17. G48V is 
associated with V82A in saquinavir resistance314,315 and this pair occurs as a mutational cluster 
together with non-active site mutant C95F, which emphasizes the importance of co-evolution of 
mutations at 48 and 82 in drug resistance. Mutations at 48 and 82 together with those at 30, 84 
and 90 are considered primary mutations that are necessary for inhibitor resistance316. The 
present structural study reveals that PRS17, a multidrug-resistant PR harboring primary 
mutations at 48 and 82 in addition to others, recognizes substrate analogs CA-p2 and p2-NC in 
an altered fashion in comparison to wild-type structures. The crystal structure of unliganded 
PRS17-D25N exhibits curling of flap tips in comparison to unliganded wild-type structure. This 
flap curling is initiated by G48V mutation with a ~172° change in  angle in comparison to PR 
wild-type and extends up to Gly52’. In addition to G48V other flap mutations M46L and I54V 
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may also contribute to curling in PRS17. Identical flap curling was observed in the recent 
unliganded PRS17 crystal structure118. Also, solution studies of PRS17-D25N by NMR 
demonstrated that the inhibitor-free PRS17-D25N adopts a flap conformation very similar to that 
of inhibitor-free active PRS17 crystal structure. The current crystal structure of PRS17-D25N 
further confirms that the conformation changes observed in the flaps of the two unliganded 
structures of PRS17 are due to the mutations. Curling or twisting of flaps in the PR structures 
due to mutations in the flaps is implicated in the altered resistance profile of the mutant PR. 
F53L single mutant which exhibits curled flaps was shown to poses 15% lower catalytic 
efficiency and 20-fold weaker inhibition by clinical drug indinavir317. Twisting of flaps observed 
in the recently reported PR with 22 mutations in addition to inactivating D25N mutation has 
>175-fold resistance to DRV in addition to APV318. The flap twisting initiated by G48V 
mutation in PRS17 is implicated in the cross resistance of PRS17 to multiple clinical drugs 
including DRV even though it lacks any major mutations associated with DRV resistance118. 
Although the binding site for P3 Arg of CA-p2 in the current PR/CA-p2 complex is 
partly exposed to solvent, P3 Arg interacts with flap residue Phe53′ in a manner similar to that 
seen in CA-p2 complexes with PR (4EP3), PRV82A (2AOE) and inactive PR-D25NV82A 
(1MT8).  With P3 Arg bound at the preferred wild-type flap binding site, mutations at 82 with 
large side-chains like V82F, V82I or V82L hinder binding of PR inhibitors thereby altering PR 
susceptibility to PI’s while retaining binding to substrates. The G48V mutation in PRS17 also 
confers resistance to PR inhibitors16, and it blocks the flap binding site for P3 Arg of CA-p2 
observed in the various wild-type PR complexes. However, V82/82′S mutation in PRS17 results 
in ~1 Å shift in the residues of the 80’s loop and rearrangement of the S3/S3’ pocket between 
V82/82′S and the conserved Arg8′/8. Both P3 Arg of CA-p2 and P3′ Arg of p2-NC bind in this 
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subsite of PRS17 with enhanced interactions including a new direct hydrogen bond, water-
mediated hydrogen bonds and van der Waals contacts to the 80’s loop that are absent in 
corresponding wild-type structures. This alternate binding site for P3/P3′ substrate residues is 
particularly critical for PR fitness when resistance mutations like G48/48′V are present at the 
flaps. The G48/48′V mutation also alters the binding of P4′ Nle of CA-p2 as well as P3 Thr and 
Ace residues of p2-NC substrate analogs.  
The enhanced binding of CA-p2 and p2-NC substrate analogs with new hydrogen bond 
interactions observed in PRS17 complexes in comparison to PR complexes agrees well with 3.4 
and 4.2-fold better Ki values for PRS17 relative to those for wild-type enzyme.  In addition, 
comparison of PRS17 substrate analog complexes with that of DRV reveals that highly multiple 
drug resistant PRS17 efficiently binds substrate analogs and DRV with minimal conformational 
changes, thereby contributing to both viral fitness and drug resistance. The current structural 
studies of PRS17 strongly suggest that G48V mutation plays an important role in the enhanced 
binding of substrate analogs CA-p2 and p2-NC. Further, the size of the mutated side-chain 
selected at residue 82 may be influenced by the presence of mutation at the flap residue Gly48. 
In the absence of G48V mutation, Val82 mutations enhance resistance profile of PR through 
steric hindrance to inhibitors at the binding site. However, in the presence of G48V flap 
mutation, mutations of residue 82 to bigger side-chains like V82F, V82L, and V82I may 
interfere with binding of substrates, while smaller V82S and V82A mutations might play vital 
role in both enhanced binding of substrate and increased resistance to PI’s through structural 
shift of 80’s loop. The structural features identified in the current studies reveal valuable 
information for the future design of drugs targeting multidrug-resistant HIV PRs. Clearly, further 
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studies on the substrate recognition by multidrug-resistant PR variants will bring out new ways 
of targeting viral fitness and activity. 
  
81 
  
Table 3.1: Inhibition constants (Ki) in nM for PR, PRV82A, and PRS17 
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Table 3.2: Crystallographic data and refinement statistics 
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Figure 3.1 Sites of mutation in PRS17 dimer and substrate analogs. 
A. Sites of 17 mutations are mapped on PRS17 dimer (cyan cartoon representation) with flap 
region in orange and bound substrate analog CA-p2 shown as blue sticks. The critical G48V and 
V82S mutations involved in substrate analog binding are shown as red spheres in each subunit. 
B. Fo-Fc omit map of CA-p2 colored by element type contoured at 2.8 level.  
C. Fo-Fc omit map of p2-NC colored by element type contoured at 3 level. 
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Figure 3.2: Altered flap of PRS17-D25N.  
A. Curling of flap due to flap mutations M46L, G48V and I54V observed in inhibitor-free 
structures of PRS17-D25N (green ribbon) and PRS17 (orange ribbon) in comparison to PR (grey 
ribbon). The circled portions of flap are magnified in sticks for inhibitor-free PRS17-D25N (green 
carbon), PRS17 (orange carbon) and PR (grey carbon).  
B. Flipped peptide bond between Ile50 and Gly51 of PRS17-D25N (green carbon) and PRS17 
(orange carbon). 
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Figure 3.3: Overall interaction of substrate analog CA-p2 with PRS17.  
A. Hydrogen bond interactions between PRS17 (green carbon) and substrate analog CA-p2 (grey 
carbon). Water molecules are shown as red spheres in this and subsequent figures. Hydrogen 
bonds are shown in black dotted lines and the new hydrogen bond observed between PRS17 and 
CA-p2 is in red dotted line.  
B. Comparison of CA-p2 P1 Leu interaction in PRS17/CA-p2 (green carbon) and PR/CA-p2 (grey 
carbon). The van der Waals contacts are represented by (−  −  −) lines in green in PRS17/CA-p2 
and in black in PR/CA-p2 complex. 
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Figure 3.4: Interactions of P3 and P4 of substrate analog CA-p2 with PRS17.   
A. Interaction of P3 Arg of CA-p2 (conformation1) in dimer 1 of PRS17/CA-p2 (green carbon) 
and PR/CA-p2 (grey carbon). The hydrogen bonds common to both the complexes are shown in 
purple dotted lines. In all sub panels, new hydrogen bonds observed in PRS17/CA-p2 complex are 
shown in red dotted lines. The van der Waals contacts are represented by (−  −  −) lines in green 
in PRS17/CA-p2 and in black in PR/CA-p2 complex.  
B. P3 Arg of CA-p2 (conformation 2 and 3) in dimer 2 of PRS17/CA-p2 (green carbon). 
Interactions of conformations 2 and 3 are shown in panels C and D respectively.  
C. Interactions of P3 Arg conformation 2 in dimer 2 of PRS17/CA-p2 (green carbon) in 
comparison to PR/CA-p2 (grey carbon).  
D. Interactions of P3 Arg conformation 3 in dimer 2 of PRS17/CA-p2 (green carbon) in 
comparison to PR/CA-p2 (grey carbon).  
E. Interactions of major conformation P3 Arg (salmon carbon) and minor conformation P4' Nle 
(magenta carbon) of V82A single mutant complex PRV82A/CA-p2 in comparison to PRS17/CA-p2 
(green carbon). The van der Waals contacts of P3 Arg of PRV82A/CA-p2 are shown in black 
while those of P4' Nle are shown in magenta.  
F. Difference in the binding of P4 Nle between PR/CA-p2 dimer1 (grey carbon) and PRS17/CA-
p2 (green carbon). The hydrogen bond present only in PRS17/CA-p2 is colored in green, and the 
hydrogen bond present in PR/CA-p2 complex alone is shown in black dotted lines. 
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Figure 3.5: Binding of P3, P3 and P4 residues of p2-NC and DRV to PRS17.  
A. The P3' Arg forms new hydrogen bond and van der Waals contacts colored in red with Pro81 
of PRS17/p2-NC (orange carbon) in comparison to PR/p2-NC (grey carbon, 2AOD).  
B. The difference in P3 Thr interactions between PRS17/p2-N (orange carbon) and PR/p2-NC 
(grey carbon). The three new hydrogen bonds observed in PRS17/p2-NC are colored in red. The 
minor conformation of Arg8' observed in PR/p2-NC was omitted for clarity. The van der Waals 
lines in this panel show residues in contact and may have more than one interaction between the 
residues.  
C. Superposition of active site cavity of PRS17/CA-p2 (green carbon), PRS17-P41/p2-NC (orange 
carbon) and PRS17/DRV (grey carbon, 5T2Z). DRV bound at the active site is shown in magenta 
sticks. The hydrogen bond interactions between DRV and PRS17 are shown in dotted lines. For 
the sake of clarity, water-mediated hydrogen bonds between DRV and the flaps are omitted. 
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4 HIGHLY DRUG-RESISTANT HIV-1 PROTEASE REVEALS DECREASED INTRA-
SUBUNIT INTERACTIONS DUE TO COORDINATED STRUCTURAL CHANGES 
IN CLUSTERS OF MUTATIONS 
Kneller, DW, Agniswamy, J, Harrison, RW, Weber, IT. (2019) Highly drug-resistant HIV-1 
protease reveals decreased intra-subunit interactions due to coordinated structural changes in 
clusters of mutations. In revision, The FEBS Journal. 
4.1 Abstract 
Drug resistance is a serious problem for treatment of the HIV/AIDS pandemic. Potent 
clinical inhibitors of HIV-1 protease show several orders of magnitude worse inhibition of highly 
drug resistant variants. Hence, the structure and enzyme activity were analyzed for HIV protease 
mutant PRS5B from a clinical isolate that was selected by machine learning to represent high 
level drug resistance. PRS5B has 22 mutations including only one (I84V) in the inhibitor-binding 
site, however, clinical inhibitors had poor inhibition of PRS5B activity with Ki values of 4-1000 
nM or 18-8000-fold worse than for wild-type PR. High resolution crystal structures of PRS5B 
complexes with the best inhibitors, amprenavir and darunavir (Ki ~4 nM), revealed only minor 
changes in protease-inhibitor interactions. Instead, two distinct clusters of mutations in distal 
regions induce coordinated conformational changes that decrease favorable internal interactions 
across the entire protein subunit. The largest structural rearrangements are described and 
compared to other characterized resistant mutants. In the protease hinge region, the N83D 
mutation eliminates a hydrogen bond connecting the hinge and core of the protease and increases 
disorder compared to highly resistant mutants PRS17 and PR20 with similar hinge mutations. In a 
89 
distal β-sheet, mutations G73T and A71V coordinate with accessory mutations to bring about 
shifts that propagate throughout the subunit. Molecular dynamics simulations of ligand-free 
dimers show differences consistent with loss of interactions in mutant compared to wild-type PR. 
Clusters of mutations exhibit both coordinated and antagonistic effects suggesting PRS5B may 
represent an intermediate stage in the evolution of more highly resistant variants.      
4.2 Introduction 
Globally, human immunodeficiency virus (HIV) is estimated to infect 36.7 million 
people5. Treatments using a combination of inhibitors targeting HIV entry/fusion steps and the 
viral enzymes, reverse transcriptase (RT), integrase, and protease (PR), have greatly improved 
patient outcomes. However, HIV resistance to all current drugs is a serious problem due to the 
presence of numerous genomic polymorphisms and rapid evolution of virus319. Moreover, 
expansion of antiretroviral therapy has resulted in infection with virus resistant to RT inhibitors 
in greater than 10% of untreated individuals in some countries33. Thus, recent WHO guidelines 
promote second-line PR inhibitor (PI) treatments.  
HIV evolves resistance to PIs primarily by mutations in the PR gene320. HIV-1 PR is 
required for proteolytic cleavage of Gag and Gag-Pol precursor polyproteins into individual 
proteins during viral maturation, and is essential for producing infectious virus86. The enzyme 
forms a dimer of 99-residue subunits. Mutations in over 50% of the PR residues are associated 
with resistance to all current clinical PIs and lead to decreased effectiveness and treatment failure 
164. Major mutations produce drug resistance by three general molecular mechanisms: mutations 
of residues in the inhibitor binding site can directly alter PR-PI interactions; some distal 
mutations confer drug resistance by altering dimerization via changes in inter-subunit 
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interactions; and other distal mutations, such as L76V, can destabilize the dimer and decrease PI 
potency by creating structural rearrangements in key locations of the protease163,172,176–178.  
During drug treatment, the virus can evolve increasingly higher levels of resistance by 
combining major mutations with additional accessory or compensatory mutations321 which can 
persist even after termination of treatment322. Several well characterized PR mutants include 
about 20 different mutations and show several orders of magnitude decreased susceptibility to 
clinical inhibitors 165. Two such variants, PR20 and PRS17, form stable dimers with 2-4-fold less 
efficient Gag processing compared to wild-type PR while maintaining the same order of 
cleavage 137,193,206. Mutations in PR20 coordinate to expand the binding cavity for inhibitors, 
consistent with dramatically decreased binding affinity. Analysis of ligand-free and darunavir 
(DRV)-bound X-ray crystal structures of PR20 and PRS17 showed clusters of mutations in the 
hinge and flap regions conferring changes in conformation of the flaps118,192. Nuclear Magnetic 
Resonance (NMR) spectroscopic analysis of ligand-free PR20 and PRS17 demonstrated that these 
mutants tend to exist in an open-flap conformation in the absence of inhibitor, while wild-type 
enzyme preferentially occurs in the closed conformation, even in the absence of inhibitor118,323. 
These changes in PR structure and dynamics are proposed to be important for acquiring high 
level resistance to PIs118.  
Here, we have investigated the enzyme kinetics and inhibitor-bound structures of an HIV 
protease mutant with 22 substitutions from a resistant clinical isolate, dubbed PRS5B. Like 
PRS17, the mutant was selected as a representative of highly drug-resistant PR by mean-shift 
clustering on genotype-phenotype data in Stanford HIVdb 300,324 using a unified encoding of the 
sequence and 3-D structure202–204. In this procedure, PRS17 was the sole mutant common to the 
clusters with highest level resistance for each of six PIs, whereas PRS5B mutant was the second 
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most common mutant predicted to represent high-level resistance to only five PIs: atazanavir 
(ATV), nelfinavir (NFV), indinavir (IDV), tipranavir (TPV), and saquinavir (SQV). Two 
mutations in PRS5B have a major association with drug-resistance (M46L and I84V), while nine 
are classified as minor drug resistance mutations (L10I, V11I, M36I, I54V, I62V, I63P, I64V, 
A71V, and G73T)164. Mutation N83D is classified solely as a major resistance mutation for 
TPV164. Here, we confirmed by enzyme kinetics experiments that these drugs, in addition to 
lopinavir (LPV), amprenavir (APV), and DRV, have significantly worse inhibition for PRS5B 
relative to wild-type PR. Analysis of X-ray crystal structures of PRS5B in complexes with DRV 
and APV revealed how mutation clusters in distal regions of the protease may contribute to drug 
resistance via long-range indirect effects. The PRS5B structures are compared to PRS17 and PR20 
complexes with the same inhibitors. Conformational variation of PRS5B and wild-type PR in the 
absence and presence of inhibitors is explored by molecular dynamics (MD) simulations. These 
studies illuminate how HIV PR can evolve drug resistance through synergistic effects of clusters 
of mutations in regions far from the inhibitor binding site. This information will be advantageous 
for improving inhibitor design against highly drug resistant virus.   
4.3 Methods 
4.3.1 Selection of the PRS5B sequence 
The protein sequence for PRS5B was obtained by the same machine learning procedure 
described for PRS17. Mutants representing broad classes of high level resistance to each inhibitor 
were selected by mean shift cluster with regression analysis of genotype-phenotype data in the 
Stanford HIVdb (https://hivdb.stanford.edu) 204. The procedure used a unified encoding of the 
sequence and 3D structure as described in 204.  Only a single mutant, PRS17, was observed in the 
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highest resistance bin for 6 inhibitors. PRS17 and PRS5B mutants were identified as representing 
high resistance to different combinations of 5 inhibitors.  
4.3.2 Expression and purification of PRS5B  
The gene coding for PRS5B was synthesized and cloned on a pJ414 plasmid with a T7 
promoter [ATUM] and transformed into E. coli BL21 (DE3) (Invitrogen) cells138. PRS5B 
contains additional mutations Q7K to reduce autoproteolysis and C67A and C95A to eliminate 
cysteine thiol crosslinking325,326. Protein expression, purification, and folding were performed as 
described287,288.    
4.3.3 Enzyme kinetic assays  
Kinetic experiments and enzyme dilutions were carried out in reaction buffer (50 mM 
MES pH 5.6, 200 mM sodium chloride, 0.5 mM EDTA, and 2.5% glycerol final reaction 
concentration). PIs obtained from the NIH AIDS Reagent program were dissolved in 100% 
DMSO. A spectroscopic fluorescence resonance energy-transfer (FRET) substrate analog 
derived from the HIV-1 Gag p2/NC cleavage site (H-2992 – BACHEM, Bubendorf, 
Switzerland) was used to monitor the initial rate of substrate hydrolysis by PRS5B at 37°C. The 
enzyme kinetic parameters (kcat, Km of FRET substrate, and kcat/Km) and inhibition constants (Ki) 
were determined as described in 207. Enzyme concentration [E] was determined using active site 
titration with tight-binding inhibitor, APV. Ki was obtained from the equation Ki = (IC50 − 
[E]/2)/(1 + [S]/Km). Values are reported as mean ± SD (n=3-5).    
UC50 for PRS5B, PR
S17, and PR20 were measured using the same reaction buffer, 
substrate, enzyme, and temperature conditions as Ki measurements with the addition of 0-1.2 M 
urea as described in 327. Values are reported as mean UC50 ± 3 standard deviations (n=3-4) where 
UC50 = urea concentration at 0.5 velocity at 0 M urea. 
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4.3.4 Crystallization and X-ray structure determination 
Inhibitor dissolved in 100% DMSO was mixed at an 8:1 molar ratio with 4.2 mg/mL 
PRS5B solutions and incubated on ice for 30 minutes. Crystallization of the complexes were 
performed using hanging-drop vapor diffusion at room temperature using 1 µL protein/PI 
complex and 1 µL reservoir solution. Crystallization conditions for PRS5B/DRV were 2.2 M 
Ammonium Phosphate and 100 mM Tris buffer at pH 7.9. PRS5B/APV crystallized in 1.8 M 
Ammonium Phosphate and 100 mM Tris buffer at pH 7.9. Crystals grew after approximately 14 
days and were cryo-protected stepwise in reservoir solution with 30% glycerol. Diffraction data 
were collected at 100°K on SER-CAT beamline 22-ID at the Advanced Photon Source, Argonne 
National Laboratory (Argonne, IL, USA).     
 Diffraction data were integrated and scaled using HKL2000271. The crystal 
structure of PRS5B/DRV was solved by molecular replacement in Phaser using PR/DRV (2IEN) 
as a search model272,289. The refined PRS5B/DRV structure was used as a search model for 
PRS5B/APV. Integrative rounds of refinement using COOT274 and REFMAC5293 were used to 
construct the atomic models. In each structure, the inhibitor was fitted during refinement into 
unambiguous electron density in a single conformation. Statistical information was gathered 
using baverage and superpose328. Hydrogen bond interactions and van der Waals contacts were 
inferred from interatomic distances in the ranges of 2.4-3.4 Å and 3.0-4.2 Å, respectively. 
Structural figures were prepared using PyMOL276.  
4.3.5 Molecular dynamics simulations 
Molecular dynamics (MD) simulations were performed for two ligand-free (PRS5B and 
PR) and four inhibitor-bound structures (PRS5B/APV, PRS5B/DRV, PR/APV and PR/DRV). 
The starting models were the wild-type PR complexes with DRV (PDB: 2IEN304) and APV 
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(PDB: 3NU3166) and the corresponding complexes of the PRS5B mutant (PDB: 6P9A and 
6P9B). Alternate conformations were deleted from the models, keeping the majority 
conformation. Inhibitors were removed for MD simulations of the ligand-free proteases. Solvent 
molecules from the crystal structures were included in the simulations and a mobile proton (H+) 
was introduced between the carboxylates of the catalytic Asp25 and 25’ to enable the protein to 
assume the variable protonation states observed in different neutron structures of HIV 
PR124,133,329. Each dimer was solvated with about five thousand water molecules generated 
randomly to fill the free space within a 30Å shell of the protein. Energy minimization and MD 
simulations used the program, AMMP330 with the Tuna potential set331, a modification of the SP4 
set described in 332 with charges updated to those of Amber ff14SB333. In tests on small molecule 
benchmarks, the potential sets compare well to the CHARMM and AMBER sets332. AMMP is 
the molecular mechanics and dynamics engine of VegaZZ334 and has undergone extensive 
professional code review as part of the SPEC2000 benchmark335. It is designed to be a 
computational backend that is plugged into other programs.  
Positions were calculated for all hydrogen atoms and the geometry of the solvated protein 
system was minimized by conjugate gradients prior to starting the MD simulations. All-atom 
simulations were performed as described in 194,336. The aperiodic amortized fast multipole 
algorithm was used for the electrostatic and non-bonded terms with parameters (mxdq = 0.75 Å; 
mmbox = 10.0 Å), 300K temperature constrained with Nose constraints, and a bounding volume 
constraint of 35 Å. Frames were saved for every 1 pc during the 10-20 ns simulations. The 
RMSD values and variance from the mean were calculated after superimposing each frame on 
the starting model. Selected interatomic distances were calculated using Python programs. The 
structural variation during the simulations was examined in a gif of the consecutive frames. 
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4.4 Results 
4.4.1 Enzyme kinetic parameters 
Kinetic parameters for PRS5B were determined using a FRET-based assay that employed 
a substrate analog of the p2/NC cleavage site. The measured kcat of 109 ± 20 min
-1 for PRS5B is 
~2-fold lower than for wild-type PR (194 min-1), and PRS5B exhibits 5-fold higher Km of 160 ± 
45 µM relative to PR (30 µM)298. The catalytic efficiency of PRS5B (kcat/Km = 0.69 ± 0.07 µM
-
1min-1) is comparable to that of PRS17 (0.49 µM-1min-1) under identical conditions207 and close to 
that of PR20 (0.35 µM-1min-1) measured under different conditions with chromogenic 
substrate137. All three of these highly resistant mutants show about 10 to 20-fold reduced 
catalytic efficiency compared to PR (6.5 µM-1min-1 for FRET-substrate at 26 °C).           
Inhibition constants of 8 PIs measured for PRS5B are compared with previously reported 
values for wild-type enzyme 206,337 in Table 1. The PIs showed Ki values of 4-1000 nM for 
PRS5B, or 18-8,000-fold worse than for wild-type enzyme. Machine-learning predictions 
suggesting resistance to inhibition by TPV, ATV, NFV, IDV, and SQV for PRS5B were 
confirmed by these enzyme inhibition results. PRS5B was poorly inhibited by SQV (2,500-fold 
relative to wild-type PR) and LPV (8,000-fold), while significantly worse inhibition of 40 to 
800-fold was measured for DRV, ATV, TPV, NFV, and IDV. The lowest Ki value (3.6 nM) and 
relative inhibition (18-fold) for PRS5B was shown for APV, however, DRV also had a Ki of 4.0 
nM. LPV showed significant resistance, although not the highest level, in the Stanford HIV 
database PhenoSense® assay for the isolate with PRS5B, which explains why resistance to this 
inhibitor was not identified in the mean-shift clustering analysis. DRV and APV PhenoSense® 
data were absent from the Stanford database at the time of the machine learning training. The 
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lower resistance reported from the cell-based PhenoSense® assay compared to that observed by 
kinetics with the purified enzyme reflects differences between the two assays. Such 
discrepancies reinforce the importance of not over-training machine learning models for drug 
resistance. 
4.4.2 Drug-resistance mutations do not significantly affect protease sensitivity to urea 
Proteolytic activity of PRS5B, PRS17, and PR20 was measured for a range of urea 
concentrations to assess sensitivity to denaturation. Loss of proteolytic activity in the presence of 
urea has been shown to reflect the unfolding process287 and provides a chemical-based assay of 
enzyme stability. UC50 values for PRS5B, PR
S17, and PR20 were measured to be 0.50 ± 0.21, 
0.64 ± 0.18, and 0.73 ± 0.24 M, respectively, or very similar to the value measured for wild-type 
PR (0.7 M)327. 
For some mutants, increased sensitivity to urea denaturation is observed together with 
increased Kd for dimer dissociation relative to values for wild-type enzyme. For PR with single 
substitution of L76V (PRL76V), two-fold increased susceptibility to denaturation by urea was 
accompanied by a 7-fold higher dimer dissociation constant (Kd) relative to wild-type enzyme, 
although the catalytic efficiency was unchanged 177. PR20 also showed 5-fold higher Kd relative 
to wild-type enzyme193, although PR20 and PR have similar UC50 values indicating no 
association between the different measures of stability. PRS17 exhibited similar Kd
177 and UC50 
values as wild-type enzyme, despite structural evidence for fewer intersubunit contacts118. 
Variants with multiple mutations can harbor substitutions conferring compensatory effects to 
restore dimer stability.  Therefore, unlike PRL76V, the three drug resistant mutants with multiple 
substitutions and lower catalytic efficiency do not exhibit altered protein stability in the presence 
of urea.      
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4.4.3 Overall Structure and designation of clusters 
X-ray crystal structures of PRS5B in complexes with DRV and APV were solved at 1.66 
and 1.75 Å resolution, respectively. Data collection and refinement statistics are listed in Table 2. 
Both structures were solved in the tetragonal space group P43212 with one dimer per asymmetric 
unit. Structures of PRS5B/DRV and PRS5B/APV were refined to Rwork/Rfree of 0.18/0.21 and 
0.18/0.22, respectively. Each dimer is numbered 1-99 for subunit A and 1′-99′ for subunit B 
corresponding to the orientation of the single conformation for the two peptidomimetic 
inhibitors. In both complexes, side chains of mutations were unambiguously modeled with three 
exceptions. Local side chain disorder was observed near the mutations E35N and S37D in 
subunit A, likely due to lack of crystal contacts as observed for subunit B and the clusters of 
mutations leading to loss of interactions in this region. The side chain atoms of mutated residue 
R41K show no electron density in both subunits. The basic side chain of residue 41 occurs at a 
polymorphic site on the protein surface. In the absence of crystal contacts, this side chain is 
typically disordered in PR structures. Alternate conformations were observed for main chain 
residues 34 and 35 in the hinge region as described in a later section.  
The dimer of PRS5B/DRV is shown in Figure 4.1 with key structural regions and 
mutation clusters labeled. Each protease monomer contains three major elements. The flaps 
(residues 42-56) control access to the active site and are important for binding of substrates and 
inhibitors. The dynamic flaps pivot about the hinge-loop (residues 34-41) which interacts with 
the main body of the protease at the 80’s loop (residues 78-85) and two other β-strands. The β-
strand of the protease flap continues into two-stranded β-sheet referred to here as Loop 2 
(residues 61-76). Loop 2 adjoins another two-strand antiparallel β-sheet, Loop 1 (residues 10-
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21), to form a 4-strand β-sheet that wraps around the sole α-helix (residues 87-93). Hydrophobic 
residues facing the center of this assembly create the hydrophobic core of the protein. 
PRS5B contains 22 mutations, including only a single mutation (I84V) in the inhibitor 
binding site and two mutations (M46L and I54V) in the flaps. The other mutations fall into two 
main clusters, designated after the major protease regions they affect. Hinge and Loop 2 
mutation clusters show coordinated effects on the hinge and Loop 2 regions of the protease 
respectively. Two additional mutations in Loop 1 bring about minor effects. The mutation 
clusters in PRS5B and in previously characterized drug resistant mutants PRS17 and PR20 are 
shown in Figure 4.1. The three PR mutants share a common cluster of mutations in the hinge 
region. Within each hinge mutation cluster, E35N/D and M36I are shared, although each mutant 
contains different accessory mutations. PRS17 contains a cluster of three flap mutations,  M46L, 
G48V, and I54V, which primarily affect the conformation of the flaps118,207. PR20 shows an 
expanded inhibitor binding cavity due to a cluster of mutations (D30N, V32I, I47V, and 
I84V)191,192. Mutation L10I in Loop 1 of PRS5B was excluded from the designated clusters due 
to absence of significant structural changes as also seen for the same mutation in the PRS17/DRV 
structure. In PR20, however, a phenylalanine substitution at this position is associated with loss 
of an intersubunit ion pair between the nearby Arg8 and Asp29′ 137,191.  
 The 198 Cα atoms of PRS5B/DRV dimer superimpose on equivalent atoms of 
wild-type PR/DRV (PDB:2IEN304) with a root mean square deviation (RMSD) of 0.94 Å. The 
hinge and Loop 2 regions of PRS5B/DRV show the largest structural changes relative to 
PR/DRV suggesting an effect from the local mutation clusters in those regions. Likewise, the Cα 
atoms of PRS5B/APV superimpose onto PR/APV dimer (PDB: 3NU3166) with a RMSD of 1.02 
Å. PRS5B/APV exhibits larger shifts in the hinge and Loop 2 relative to PR/APV compared to 
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the corresponding DRV complexes. The two structures of PRS5B with DRV and APV are 
essentially identical and superimpose with a low RMSD of 0.16 Å. 
4.4.4 PRS5B inhibitor-binding site and flaps 
The inhibitors and their interactions with PRS5B are shown in Figure 4.2. The two 
inhibitors are chemically similar, apart from a bis-tetrahydrofuran (THF) moiety at P2 in DRV in 
place of the single THF ring of APV (Figures 4.2A and D). Both inhibitors bind to the active site 
of PRS5B in a single conformation, possibly due to crystallizing in the P43212 space group, 
unlike many crystal structures of PR-PI complexes that show inhibitor bound in two orientations 
related by 180°. The hydrogen bond interactions with inhibitors (Figures 4.2B and E) are 
conserved in PRS5B and wild-type PR complexes. The P2 THF group of APV accepts a 
hydrogen bond from the backbone amine of Asp30. In DRV, the P2 bis-THF group conserves 
this interaction in addition to forming hydrogen bonds with the amine of Asp 29. However, these 
additional interactions of DRV relative to APV do not alter the inhibition of PRS5B (Table 4.1).   
I84V is the sole mutation in PRS5B with a side chain that faces the active site cavity. 
This mutation contributes resistance to all PIs164. Substitution of the smaller valine side chain at 
residue 84 increases the volume of the S2/S2′ pockets and results in fewer van der Waals 
contacts with APV compared to the PR complex (Figures 4.2C and F).  
The side chains of flap mutations M46I and I54V do not form van der Waals contacts 
with these inhibitors. The single substitution of I54V in PR has been described previously to alter 
flap conformation and effect inhibitor binding 298. This mutation is associated with resistance for 
all PIs except DRV 164. In PRS5B structures, the shorter sidechain of I54V decreases 
hydrophobic interactions with the Ile50 side chain on the opposite subunit. PRS5B contains a 
second flap mutation M46I, which is a drug resistance mutation for all clinical PIs except DRV, 
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SQV and TPV164. The side chain of flap residue 46 is adjacent to Phe53 at the protein surface, 
however, the shorter hydrophobic side chain of M46I shows no significant effects on the flap 
structure of PRS5B inhibitor complexes. M46I and I54V mutations co-occur frequently in drug 
resistance 337–339. Adding M46I and I54V mutations to a RTV-resistant mutant was shown to 
improve catalytic efficiency while sustaining resistance 291. Molecular dynamics simulation 
suggests these mutations may act by altering the flexibility of the flaps 340.  
4.4.5 Hinge cluster mutations E35N and M36I coordinate with N83D to disengage flaps   
Comparison of the new PRS5B structures with equivalent PR, PRS17, and PR20 
complexes illustrates how the addition of N83D induces more extensive loss of interactions at 
the hinge-body interfaces than seen for previously characterized highly-resistant mutants lacking 
this mutation. The PDB codes used for comparison are as follows: PR/APV=3NU3, 
PR/DRV=2IEN, PRS17/DRV=5T2Z, PR20/DRV=3UCB, PR20/APV=4J5J. Consistent changes 
were observed in both PRS5B/DRV and PRS5B/APV structures. Structurally, the hinge 
(residues 34-41) is an anchoring point for the base of the flexible flap (residues 42-56). 
Mutations in the hinge region are known to increase flap flexibility and contribute to drug 
resistance in PR20, PRS17, and other mutants118,186,191,192,337,341.  
 PRS5B harbors 4 mutations in the hinge, E35N, M36I, S37D, and R41K. Only 
M36I is associated with resistance to ATV, IDV, NFV and TPV, while the other hinge mutations 
have no significant association with resistance 164. The side chain of residue 34 shows altered 
interactions with mutated residue N83D in the 80’s loop in the core of the dimer. With the 
exception of subunit A of PRS5B/DRV, hinge residues 34 and 35 display alternate 
conformations for the main chain, while the side chains of Glu34 and E35N show alternate 
conformations or disorder. Intermolecular crystal contacts partially mitigate the disorder in 
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subunit A. Therefore, the extent of changes arising from hinge-loop mutations is described for 
subunit B and compared to PR (Figure 4.3). The loss of charge due to the E35N mutation in 
PRS5B eliminates the ion pair in wild-type enzyme between the side chains of Glu35′ and flap 
residue Arg57′ (Figure 4.3A). In PRS5B/APV, loss of this ionic interaction leads to a 2.8 Å shift 
in positions of Cα atoms for residue 35 and 7 Å shift in side chain position compared to wild-
type PR. Furthermore, this change allows the Arg57′ side chain to move to a conformation which 
eliminates its hinge-flap hydrogen bond interaction with the carbonyl oxygen of Met36′. The 
new conformation of Arg57′ also retains a hydrogen bond with Tyr59′ and introduces new intra-
flap π-interaction with the side chain of Trp42′. In the absence of stabilizing crystal contacts, the 
side chain of E35′N shows little electron density suggesting the mutated side chain does not form 
any significant new interactions compared to PR.    
 Glu34′ is the first residue in the hinge of PR. Its carboxylate side chain faces in 
the opposite direction to Glu35′ to form a bifurcated hydrogen bond with the side chains of 
Asn83′ in the body of the protease and Lys20′ in Loop 1 (Figure 4.3B). In this way, Glu34′ and 
Glu35′ of the hinge link the flap to the rest of the protease. These interactions are disrupted in 
PRS5B due to the N83D mutation. The pH for the crystallization and enzyme assay conditions 
(7.9 and 5.6) likely mean Asp83 is monoprotonated. N83D introduces a negatively charged 
carboxylate group and eliminates the hydrogen bonds with Glu34′ side chain and with the 
backbone carbonyl oxygen of Glu21′. Instead, the carboxylate side chain of Glu34′ shifts by ~6 
Å away from the hinge-body interface to the protein surface of PRS5B/APV structure. The void 
left by the shifted Glu34′ side chain is filled by a single partial-occupancy water molecule that 
bridges the N83′D and Lys20′ side chains.  
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Met36′ in PR/DRV and PR/APV structures interacts with nearby side chains of Leu33′, 
Leu38′, and with Ile15′ in Loop 1. The hinge mutation M36I substitutes a shorter hydrophobic 
side chain. As shown in Figure 4.3C, the smaller M36I residue in PRS5B structures retains 
significant van der Waals contacts with Ile15′ and Leu38′ and the mutated I33L sidechain due to 
a shift in its main chain. The Cα of Ile36 is closer to Loop 1 by 1.3 and 1.9 Å in mutant 
complexes with DRV and APV structures, respectively, compared to PR structures. Mutations 
E35N and N83D drive two alternate conformations for the main chain of the hinge-loop at 
residues 34′ and 35′ through decreased interactions with 80’s loop and flap. By allowing a 
continuation of van der Waals contacts at the hinge-Loop 1 interface using a shorter side chain, 
M36I counterbalances the effects of E35N and N83D and stabilizing the hinge-loop. Coordinated 
substitutions of M36I and I33L maintain van der Waals contacts between the hinge and Loop 1, 
thus counteracting the loss of interactions of hinge with main chain of residue 21′ and flaps in 
mutant.  
Comparison of the PRS5B/DRV hinge-region mutations with those in the DRV 
complexes with PRS17 and PR20 (Figures 4.3D and E) highlights the influence of the N83D 
mutation. Despite the presence of several mutations, introduction of a partially occupied (0.5) 
water molecule in PRS5B preserves many interactions of residues 20, 21, 34, 35 and 83 seen in 
the other two resistant mutants. All three resistant proteases have mutations for Glu35 (E35N or 
E35D) that break the ion pair with flap residue Arg57′ and a compensating M36I. However, 
PR20/DRV and PRS17/DRV lack the alternate main chain conformation of hinge-loop and side 
chain disorder exhibited by PRS5B/DRV. In PRS17/DRV, the E35D side chain forms an ion pair 
with K20R and a hydrogen bond with the side chain of Asn83′. PR20 does not contain a 
substitution for Asn83′ and thus retains the stabilizing interactions between the protease body 
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and the hinge-loop. PR20 utilizes a full-occupancy water molecule interacting between Asn83′ 
and the main chain amide of residue 35′. Unlike PRS5B, both PRS17 and PR20 preserve the 
hydrogen bond between Asn83′ and the main chain carbonyl of Glu21′ that helps stabilize the 
body of the protease and Loop 2 with the hinge. PRS17 and PR20 also have additional 
compensating mutations that act synergistically with M36I (K20R in PRS17 and I33F, I13V and 
I15V in PR20) to further stabilize the hinge.  
4.4.6 Mutations A71V and G73T coordinate with accessory mutations L11I, A22V, L24M, 
and I62/64/66V to induce structural shifts in Loop 2 
Mutation A71V is associated with resistance to all PIs except for DRV, APV and TPV, 
while G73T only shows significant resistance to ATV. Comparison of both PRS5B/PI structures 
with analogous wild-type complexes reveals how G73T and A71V mutations act in synergy with 
other accessory mutations to drive structural shifts of almost 3 Å in Loop 2 in both subunits. This 
section describes the PRS5B/APV complex specifically unless noted. Subunit B of PRS5B/APV 
is compared with wild-type structure in Figure 4.4. 
 Gly73 is situated at the top of Loop 2 where the Cα forms van der Waals contacts 
with the side chain of Leu89 (Figure 4.4A). In the wild-type PR, the large Leu89 side chain fits 
snugly into the hydrophobic core making contacts with Ile64, Thr31, Ile66, and Ala71. In 
PRS5B, Gly73 and Ala71 are replaced with larger residues, threonine and valine, respectively. 
The polar side chain of G73T is stabilized by hydrogen bonds with the side chain of Glu92 in a 
shifted conformation. In addition, subunit B of both PRS5B structures features a water molecule 
amidst this formerly non-polar core. This new water molecule forms a set of hydrogen bond 
interactions with the carbonyl oxygen of Thr74, the side chain hydroxyl groups of Thr31 and 
mutated Thr73, and the side chain of Asn88 (Figure 4.4B). More importantly, the larger side 
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chain of G73T induces a 180° flip in the bulky Leu89 side chain where the Cγ atom is ~2.5 Å 
from the position in PR. The flipped Leu89 side chain is directed toward the new bulkier side 
chain of the A71V mutation and retains hydrophobic contacts with the larger side chains of 
mutated Val71 and Thr73. Together, these substituted residues combine with other compensatory 
mutations to initiate a 1.2-3.0 Å outward shift in all Cα atoms of Loop 2 from mutated I64V 
through G73T.  
The coordinated effects of G73T, A71V, and flipped Leu89 conformation combine with 
clustered accessory mutations to bring about rearrangements in the Loop 2. Larger hydrophobic 
residues from mutations L11I, V22I, and L24M are located deep within the hydrophobic core of 
the protease and near the main chain of catalytic Asp25/25′. These three mutations help to fill 
voids in the hydrophobic core created by the shift of Loop 2 and propagate changes from Loop 2 
to the catalytic site.  
The bulge in Loop 2 induced by G73T and A71V is offset by ~1 Å due to smaller side 
chains in the I62V, I64V and I66V mutations, which have a compensatory effect (Figure 4.4C). 
Three other mutations in this cluster, Q61H, I63P, and I72V, project to the protein surface and do 
not appear to induce changes in the interior. Thus, the large distal movements for Loop 2 
stemming from A71V and G73T mutations are compensated by repacking of the hydrophobic 
core from other mutations in the cluster.    
Consequences of Loop 2 movement are best observed at the β-turn (residues 67-69) 
shown in Figure 4.5A. Large deviations in Cα atoms between PRS5B and PR structures (2.6-3.1 
Å) occur at Ala67. In PR structures, the β-turn of Loop 2 is secured to the rest of the protease by 
two interactions: an anti-parallel β-sheet hydrogen bond from the backbone amine of Ala67 to 
the backbone carbonyl oxygen of Thr12 (Loop 1) and an intersubunit ion pair from the side chain 
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of His69 to the C-terminal carboxylate of Phe99′. Both interactions are absent in PRS5B 
structures. The phenylalanine side chain of the C-terminal Phe99 interacts with Leu24, the amino 
acid adjacent to the catalytic aspartates 25/25′. The larger Met24 side chain in PRS5B displaces 
the side chain of Phe99′ by ~1.5 Å. The loss of interactions is significant as these two 
interactions contribute half of all polar contacts between Loop 2 from residues 62-73 and the rest 
of the protease present in the wild-type structures. It should be noted that the PRS5B structures 
possess no significant crystal contacts along the Loop 2 region. PRS5B structures feature 
mutations producing significant alternations of main chain conformation and repacking of 
hydrophobic side chains compared to wild-type PR structures. These changes likely result in 
altered dynamics that propagate to the active site and contribute to the poorer inhibition 
measured for clinical inhibitors.   
PRS17 and PR20 also share the A71V mutation. However, the addition of G73T combined 
with the other mutations in the cluster produces a more dramatic expansion of Loop 2 in PRS5B 
than seen in the two other drug-resistant mutants. The tips of Loop 2 and adjacent residues are 
compared for DRV complexes with PRS5B, PRS17, PR20 and wild-type PR in Figure 4.5B. In 
PRS5B, the Cα atom of Ala67′ is 2.4 and 1.8 Å farther from Loop 2 at Cα atoms of Thr12′ and 
residue 11′ than in PR, whereas there is no significant difference in these distances for PRS17 and 
PR20. Similarly, the distance between the C-terminus of Phe99 to the His69′ imidazole ring is 
~0.5 Å farther from the PR location in PRS5B compared to PRS17 and PR20. 
4.4.7 Mutation clusters decrease polar interactions across the entire monomer  
Mutation clusters at the hinge and Loop 2 are linked via mutation E21D in Loop 1.  In 
subunit B of PR/APV structure, the large side chain of Glu21′ forms a hydrogen bond with the 
hydroxyl side chain of Thr12′ linking the two β-strands of Loop 1. The shorter E21D side chain 
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in PRS5B mutant cannot form this hydrogen bond with Thr12′ side chain. Loop 1 residues 21 
and 12 provide an interface between the corresponding mutation clusters in the hinge and Loop 2 
(Figure 4.6). PRS5B has a total of six fewer polar interactions than the wild-type complex in this 
region spanning nearly the entire monomer from the C-terminus and tip of Loop 2 through the 
protease body (Loop 1 and residue 83′) to the hinge-flap interface (residues 34′-35′ to 57′).   
4.4.8 Molecular dynamics simulations explore conformational variation in PRS5B and wild-
type PR 
Since the PRS5B structures showed only minor changes in the interactions with inhibitors 
compared to wild-type complexes, MD simulations were performed to evaluate the 
conformational variation and calculate the protease-inhibitor interaction energies. Simulations of 
the ligand-free enzymes were used to assess the variation in the absence of inhibitor. Inhibitor 
APV was removed from the starting structures prior to 20 ns MD simulations of the ligand-free 
enzymes. As shown in the trajectories (Figure 4.7A), the ligand-free structures equilibrate 
rapidly to about 2.2 Å RMSD on Cα atoms. The mutant has slightly higher RMSD values than 
the wild-type PR. In comparison, earlier MD simulations starting from open conformation crystal 
structures showed RMSDs rising to 4.5 Å for PR20 mutant and about 2 Å for wild-type PR 
compared to about 1.5 Å for simulations on closed conformation dimers after removing 
inhibitor194,195,342.   
The variation in flap conformation was assessed by calculating the distances between Cα 
atoms of Ile50 and 50’ at the flap tips and the catalytic Asp 25 and 25’ (Figure 4.7B). These 
distances fluctuate during the first 15 ns and then stabilize at about 13-14 Å for mutant and wild-
type PR. The two flaps in each dimer remain closer together with the separation between Cα 
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atoms of Ile50 and 50’ at the flap tips varying around 5.8 Å for both mutant and wild-type 
protease. 
The variation in Cα positions of ligand-free dimers during the simulations is illustrated by 
the superimposed structures in Figure 4.7C. PRS5B mutant and wild-type dimers exhibit larger 
displacements from the crystal structures of 2 to 5 Å in the flaps, both strands of loop 1, the tip of 
loop 2 and the C-terminus. The mutant and wild-type PR converge into separate conformations 
in these regions. Large variations in loop 2 and the C-terminus were also described in a recent 
MD simulation by another group 343. The flaps of the wild-type dimer shift into the active site 
cavity in this orientation, whereas the mutant flaps remain closer to the conformation in the 
crystal structure. Loop 2 varies about two separate positions observed in the two crystal 
structures. Several shifts, especially those encompassing the two strands of loop 1 and the C-
terminus, are consistent with the loss of polar interactions across the subunit of PRS5B relative 
to wild-type PR observed in the crystal structures (Figure 4.6).  
MD simulations of the inhibitor-bound complexes of PRS5B/DRV, PRS5B/APV and the 
equivalent complexes of wild-type protease were run for 10 ns to assess the effect of inhibitor. 
The simulations had similar trajectories reaching about 2.2 Å RMSD from the starting structures, 
except for a slower divergence of PR/DRV to about 2.6 Å as shown in Figure 4.8A.  
The structural variation during the simulations is illustrated in Figure 4.8B. Similar to the 
ligand-free dimers, the inhibitor complexes show higher variation in the flaps, loops 1 and 2, and 
termini. In addition, the hinge shows conformational changes, especially in the APV complexes, 
while the two DRV complexes have larger differences in the strand from residues 6-10. The flaps 
of the mutant move away from the catalytic site compared to their conformation in the wild-type 
PR. Moreover, the inhibitors show greater variation in the simulations for mutant (RMSD on 
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non-hydrogen atoms of 2.3 and 1.7 Å for APV and DRV) than for wild-type PR (RMSD of 0.6 
and 1.0 Å for APV and DRV). The greater fluctuation of inhibitors in the mutant is consistent 
with greater flexibility of residues in the binding cavity and thereby poorer inhibition. Increased 
fluctuation of inhibitor was also reported in a recent MD simulation by another group344.  
The non-bonded protease-inhibitor interaction energies were calculated over the 10 ns 
simulations (Figure 4.8C). For wild-type PR, the calculated interaction energy had a mean value 
of -323.0 ± 21.6 kcal/mol for DRV and -260.4 ± 15.4 for APV. The differences are in good 
qualitative agreement with the experimental values of 40-fold higher affinity for DRV relative to 
APV. Previously, another group reported close agreement with experimental values in more 
extensive 500 ns simulations of wild-type PR with DRV and APV345. In contrast, the interaction 
energies calculated for the mutant gave a mean of -285.3 ± 16.4 for DRV and -277.9 ± 18.0 
kcal/mol for APV consistent with similar experimental inhibition values for the two inhibitors 
(Table 4.1). The calculations for mutant and wild-type complexes cannot be compared directly, 
however, since they do not account for contribution of the entropic differences in the two ligand-
free enzymes and free inhibitors in solution. These differences are likely increased due to the 
large number of mutations (22) in PRS5B, including four changes that alter the charge of the side 
chain.   
4.5 Discussion 
PRS5B is an HIV protease mutant from a clinical isolate that is poorly inhibited by all 
FDA-approved PIs as shown by enzyme kinetics experiments. Extremely poor inhibition was 
measured for LPV (Ki=160 nM) and SQV (Ki=1 µM). The best inhibitors, APV and DRV, 
displayed Ki values of approximately 4 nM for PRS5B. Structural analysis of PRS5B in 
complexes with APV and DRV demonstrates minor alteration in the inhibitor binding site, 
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consistent with the presence of only I84V mutation. The distance between closest atoms of Ile47 
and Val84 on opposite sides of the cavity increases by about 1 Å compared to the corresponding 
separation of Ile47 and Ile84 in the wild type complexes. PR20 also contains the active site 
mutation I84V, which works synergistically with 3 other mutations to substantially increase the 
size of the inhibitor binding cavity as shown by 2 Å bigger distance between the closest atoms of 
Val47 and Val84 and thus decrease the affinity for PIs. Like PRS5B, PRS17 contains only one 
active site mutation, V82S, which does not significantly alter the size of the inhibitor binding site 
or interactions with DRV relative to those of wild-type PR/DRV but may contribute to substrate 
recognition when combined with the G48V flap mutation207. These three HIV protease variants, 
PR20, PRS17 and PRS5B, display decreased affinity for DRV despite retaining all hydrogen bond 
interactions with inhibitor observed in wild-type PR crystal structures.    
In the case of PRS5B, mutations in the hinge and Loop 2 regions induce major 
conformational changes in regions distal to the active site that eliminate interactions observed in 
wild-type PR structures. Perturbations in PRS5B did not alter interactions with its two most 
effective inhibitors. Instead, significant conformational changes occurred far from the active site 
suggesting hinge and Loop 2 rearrangements lead to loss of inhibitor affinity through PI-
independent mechanisms. MD simulations also show distinct conformations for these regions in 
the mutant and wild-type PR.     
Unlike other studied examples of highly-resistant mutants, PRS5B contains a cluster of 
mutations protruding into and extending along two strands of Loop 2 (Figure 4.1). Non-active-
site mutations in this region, such as A71V and G73S, have been shown to propagate changes to 
the catalytic site and provide cross-resistance for inhibitors118,183,197,291,339,346,347. Another study 
on single mutants V32I, L33F, L76V, and L90M showed how remote mutations can impact 
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inhibitor binding by altering protein ensemble dynamics through a rearranged network of 
residues circulating to the active site179. Several molecular dynamics studies of proteins have 
shown that the effects of distal mutations can propagate to the active site and influence protein 
function348,349. These mechanisms combined with hydrophobic sliding described for HIV 
protease166,172,350 are likely occurring in PRS5B.  The dramatic perturbations resulting from the 
Loop 2 mutation cluster in PRS5B work synergistically with the hinge cluster and other 
mutations to decrease inhibitor affinity and catalytic activity.      
N83D has long been identified as a major resistance associated mutation for TPV 351–353. 
G73T is a rare minor drug resistance mutation for ATV 164,354–356. This study is the first to 
describe the structural impact of these two mutations. L10I and L63P did not show structural 
changes in PRS5B but have been shown to help maintain thermal stability when combined with 
I84V357.     
NMR measurements of inhibitor-free PRS17 and PR20, supported by molecular dynamics 
simulations and crystal structures, demonstrate that these drug resistant proteases possess 
dynamic flaps that exist preferentially in an open conformation in the absence of inhibitor. This 
is consistent with Electronic Spin Resonance experiments on PR with D30N, M36I, and A71V 
mutations358. In contrast, wild-type PR tends to adopt a closed flap conformation even in the 
absence of ligand118,193,359. PRS5B shares similar hinge-loop mutations with PRS17 and PR20. In 
addition, PRS5B bears the unique N83D mutation which leads to fewer interactions between flap 
and hinge than observed in both PRS17 and PR20. MD simulations on PRS5B show larger 
variations in the surface features of the flaps, hinge, loop 1, the tip of loop 2 and the C-terminal 
residues. Overall, the conformational differences in the MD simulations are consistent with the 
loss of hydrogen bond interactions observed across the entire subunit in the crystal structures of 
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the mutant compared to the wild-type PR. These conformational changes are expected to 
contribute to the changes in affinity for inhibitor. Protease-inhibitor interaction energies 
calculated in MD simulations agree qualitatively with the experimental difference in binding 
affinity of wild-type enzyme and mutant for DRV compared to APV.  
Comparison of the three well-characterized examples of highly resistant mutants PR20, 
PRS17 and PRS5B reveals a trajectory of how clusters of mutations might evolve to promote 
drug-resistance as illustrated in Figure 4.9. All three mutants utilize mutations in the hinge region 
at 35 and compensating M36I mutation to drive rearrangements of the hinge and alter its 
separation from the flap. PRS5B, with its unique N83D mutation, features two backbone 
conformations for a section of the hinge-loop, whereas PRS17 and PR20 contain additional 
compensating mutations in Loop 1 to stabilize the hinge. Compared to PRS5B, PRS17 and PR20 
have increasingly more effective mechanisms to compensate for loss of hinge-flap anchor point 
(Glu35-Arg57 ion pair) and show increasingly worse inhibition by PIs. PRS5B’s Loop 2 cluster 
facilitates more dramatic shifts compared to those in other mutants containing A71V, although 
three mutations serve to diminish these changes. Drug selection pressure may drive accumulation 
of mutations in protease initially towards the resistance-inducing changes in intermediate 
mutants like PRS5B, but over time, these viruses may be outcompeted by mutants with more 
synergistic mutations, such as PRS17. Other highly evolved mutants might resemble PR20 by 
introducing mutations that enhance monomer stability and expand the active site cavity or 
possess co-evolved mutations in Gag substrate cleavage sites 153.             
The PRS5B mutant provides a prime example of how mutation clusters in distal regions 
can function synergistically to decrease inhibitor effectiveness while retaining viable catalytic 
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efficiency and enzyme stability. Together, PRS5B, PRS17, and PR20 provide prototypes for the 
design of novel inhibitors to combat variations of cross-resistant mechanisms. 
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Table 4.1: Table 1: Ki values (nM) of clinical PIs for PRS5B   
PIs are listed in order of increasing Ki value for PRS5B. Ki fold change over PR calculated as Ki 
for mutant/Ki for wild-type.  
aValues from Park et al. 2016. Biochemistry, except where noted. 
bKi is from Muzammil et al. 2007. Journal of Virology [28] 
cKi from Agniswamy et al. 2013. J. Med. Chem. and Louis et al. 2011. PNAS 
Dash (-) indicates Ki is not currently published    
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Table 4.2: Table 2: Crystallographic data collection and refinement statistics for 
PRS5B/ DRV and PRS5B/APV 
Parenthesis indicate highest resolution shell. The lowest resolution shells were from 
50 Å to 3.58 and 3.77 for PRS5B/DRV and PRS5B/APV respectively.    
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Figure 4.1: Distribution of mutations in PRS5B 
A. PRS5B dimer structure in ribbon representation. Major regions of the protease are indicated 
by arrows. Catalytic Asp25/25′ and protease inhibitor DRV are shown as orange and green 
sticks, respectively. Sites of mutation are shown as spheres at the Cα position. Mutation clusters 
affecting the hinge and Loop 2 regions are colored as blue and red spheres, respectively. Active 
site mutation I84V, flap mutations M46L and I54V, and Loop 1 mutations L10I and E21D are 
shown as black spheres. Spheres hidden from view in one subunit are labeled on the opposite 
subunit. B. Structures of drug resistant mutants PRS17 (light green) and PR20 (pink) complexed 
with DRV showing mutation clusters. A mutation cluster affecting the hinge is shared by all 
three mutants as shown by blue spheres. The flap cluster in PRS17 is indicated by purple spheres. 
Mutations in PR20 altering direct inhibitor interactions are shown in teal. All other mutations are 
shown in grey. C. Amino acid sequence alignment of wild-type HIV-1 PR with PRS5B, PRS17, 
and PR20. Mutated residues are colored as in figure 1A and 1B. Identical residues are omitted. 
HIV is a pseudo-species with polymorphic populations within an infected individual. This 
consensus pseudo-wild-type PR contains mutations (*) to restrict autoproteolysis (Q7K, L33I, 
and L63I) and cysteine-thiol oxidation (C67A and C95A) and has similar catalytic properties as 
HIV PR without. For this study, substitutions from the reference wild-type are considered 
mutations in PRS5B.      
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Figure 4.2: PRS5B interactions with clinical inhibitors APV and DRV 
A. Omit map (grey mesh) for APV (orange sticks) B. APV hydrogen bonds with PRS5B. C. 
Comparison of van der Waals contacts of I84V with APV in PR and PRS5B. D. Omit map (grey 
mesh) for DRV (green sticks) E. DRV hydrogen bonds with PRS5B. F. Comparison of van der 
Waals contacts of I84V with DRV in PR and PRS5B. Omit maps are Fo-Fc maps contoured at 
3σ (grey mesh) for APV and DRV. PRS5B residues are shown as cyan sticks. PR/APV and 
PR/DRV are shown as grey sticks. Water molecules are red spheres. Van der Waals interactions 
are shown as dotted lines in red and black for PRS5B and PR, respectively.  
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Figure 4.3: Conformational changes as a result of hinge cluster mutations E35N, M36I, and 
N83D 
A. Hinge interactions for APV structures of PR (grey) and PRS5B (cyan) and conformational 
change due to E35′N. E35′N mutation eliminates ion pair with Arg57′. In PRS5B, altered 
conformation of Arg57′ forms coplanar π-interactions with Trp42′ (red dash-dots) and a 
hydrogen bond with Tyr59′. B. Rearrangements in the PRS5B hinge. Shifts due to mutations 
N83′D and E21′D alter the distribution of hydrogen bonds and introduce partial occupancy water 
molecules. C. M36′I mutation retains hydrophobic contacts (dots) with sidechains of I33′L, 
Ile′15, and Leu38′ due to shift in hinge main chain confirmation. D. Hinge of PRS5B/DRV 
(cyan) compared to PRS17/DRV (green). E. Hinge of PRS5B/DRV (cyan) compared to 
PR20/DRV (magenta). PR/APV (grey) and PRS5B/APV (cyan) carbons are shown as sticks. 
Hydrogen bonds are shown as dashes colored red for PRS5B and black for PR, PRS17, and PR20 
structures. Waters are shown as red spheres. Orange arrows indicate major shifts with distances 
in Å. Alternate conformations were omitted for clarity. 
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Figure 4.4:  G73T and A71L drive distal movement of Loop 2 through flip in Leu89 sidechain 
A. B-subunit Loop 2 of PR/APV (grey cartoon) compared to PRS5B/APV (cyan cartoon) with 
G73′T stabilizing H-bonds shown as red dashed lines. G73′T induces flipped conformation of 
Leu89′ which combines with larger A71′V side chain to rearrange Loop 2. B. New water 
molecule coordinates with Thr31′, Thr74′ and mutated G73′T. Flipped conformation of Leu89′ 
faces the valine side chain of A71′V mutation. Hydrogen bonds shown as dashed lines and van 
der Waals contacts as dotted lines. Side chains of Asn92′ and Asn88′ were omitted for clarity. C. 
Smaller hydrophobic side chains for residues 62′, 64′, and 66′ dampen distal movement of Loop 
2. Distances in Å are indicated as orange arrows.  
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Figure 4.5: Interactions of Loop 2 tip and comparison of three highly resistant mutants PRS5B, 
PRS17, and PR20 with wild-type PR 
A. B-subunit beta-loop of Loop 2 (residues 67-69) interacting with Loop 1 (residues 24 and 11-
14 shown) and the C-terminus of A subunit. PRS5B/APV is shown in cyan sticks. PR/APV is 
grey sticks. Hydrogen bonds and ion-pair are shown as dashed lines. Distances in Å are indicated 
as orange arrows. B. PRS5B Loop 2 tip comparison with drug resistant mutants PRS17 and PR20. 
Protease/DRV cartoon complexes colored as follows: Wild-type PR (grey), PRS5B (cyan), PRS17 
(green), and PR20 (magenta). Side chains for tip residues and interacting residues, including 
PRS5B mutations L24M and V11I are shown as sticks.  
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Figure 4.6: Mutations in PRS5B eliminate polar interactions spanning the length of the PRS5B 
monomer from the terminus to the flap at Arg57.   
Hydrogen bonds present in PR/APV structure and absent in the PRS5B/APV structure are shown 
as black dashes. Notable regions of the protein are labeled in red. Alternate conformations 
omitted for clarity. PR/APV (3NU3) and PRS5B/APV are shown as grey and cyan sticks, 
respectively. 
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Figure 4.7: Molecular dynamics simulations of ligand-free PR and PRS5B show conformational 
variation in the flaps, loops 1 and 2, and termini 
A. Trajectories of the simulations of ligand-free dimers. RMSD of Cα atoms after superposition 
on the starting crystal structure plotted for the 20 ns time course. PRS5B LF and PR LF 
simulations are colored in red and black respectively.  
B. Distance between Cα atoms of the flap tip (Ile50) and the catalytic Asp25 for subunit A (top) 
and subunit B (bottom) for the time course of the simulation. Plots are colored as in A.  
C. Comparison of PR and PRS5B ligand-free simulations. Snapshots of PR (grey shades) and 
PRS5B (cyan and blue) models for every 3 ns of the simulation shown as superimposed ribbons. 
The starting crystal structures of PR (black) and PRS5B (green) are shown. Labeled regions and 
red arrows indicate large conformational differences between wild-type and mutant protease. 
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Figure 4.8: Molecular dynamics simulations of inhibitor-bound PR and PRS5B give 
conformational variation and calculated non-bonded interaction energies of inhibitors 
A. Trajectories of the 10 ns simulations of APV and DRV complexes of PR and PRS5B. RMSD 
of Cα atoms after superposition with the starting crystal structure plotted for the 10 ns time 
course. Simulations are colored as follows: PR/DRV (blue), PR/APV (green), PRS5B/DRV 
(red), and PRS5B/APV (purple). 
B. Frequency plot of total non-bonded interaction energies of inhibitors in PR (left) and PRS5B 
(right) simulations. Simulations are colored as in A.  
C. Comparison of PR with PRS5B for DRV (left) and APV (right) simulations. Snapshots of PR 
(grey shades, grey inhibitor as sticks) and PRS5B (cyan and blue, orange inhibitor as sticks) 
models for every 2 ns of the simulation are shown as superimposed ribbons. The starting crystal 
structures PR (black) and PRS5B (green) are shown. Red arrows indicate large conformational 
differences between wild-type and mutant protease 
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Figure 4.9: Scheme for evolution of highly-drug resistant protease variants.  
Antiretroviral treatment with PR inhibitors selects for PR variants able to process substrate in the 
presence of inhibitors. PRS5B represents an example of an intermediate mutant protease between 
the initial accumulation of resistance-associated mutations and more highly-evolved protease 
mutants.    
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Figure 4.10: Graphical Abstract 
A mutant of HIV protease selected for high-level drug resistance by machine-learning on 
genotype-phenotype data was analyzed for the molecular basis of resistance. Clinical inhibitors 
are 20 to 8000-fold less effective on this mutant relative to wild-type enzyme. Crystal structures 
reveal conserved interactions with inhibitor. Instead, coordinated rearrangements due to two 
clusters of mutations eliminate internal interactions likely contributing to resistance. We propose 
this mutant represents an intermediate in evolution of highly-resistant HIV-1 proteases.  
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5 CONCLUSIONS 
HIV PR is a significant drug target in the global fight against the HIV/AIDS pandemic. 
Despite the success of antiretroviral therapy, drug resistance remains a threat in the wake of 
greater accessibility to ART. Structure-guided design of PIs has produced effective drugs such as 
DRV with picomolar affinity for PR. However, a greater understanding of the molecular 
mechanisms employed by DRV-resistant mutants, such as PR20, PRS17, and PRS5B, is 
important in order to devise new structure-guided design strategies to stem the increasing trend 
of drug-resistant PRs. This research expands our understanding of how mutations in these three 
highly-resistant PRs clinical isolates cooperate to lower susceptibility to PIs.  
 PR20 is an excellent prototype to test the inhibition of investigative compounds on due to 
its expanded ligand-binding site, highly mobile flaps, and greater dimer dissociation constant. A 
new compound, GRL-142, showed 16-fold better inhibition than DRV of PR20. Comparison of 
PR20/GRL142 and PR20/DRV crystal structures revealed that the bulkier P2 and P2′ groups on 
GRL-142 fill the expanded ligand-binding site of PR20 and the di-fluorinated P1-benzyl 
introduced a fluorine-bond bridge and restored an important inter-subunit ion pair. These insights 
show how strategies for drug-design incorporating larger and halogenated moieties onto the 
DRV scaffold can inhibit highly-mutated PR variants better than does DRV.  
 Viable Gag and Gag-Pol processing in the presence of inhibitors is required for positive 
selection of PR mutants, such as PRS17. Substrate analogs of Gag cleavage sites p2-NC and CA-
p2 exhibited 3-fold better inhibition of PRS17 compared to wild-type enzyme. Crystallographic 
analysis of PRS17 complexed with p2-NC and CA-p2 revealed how mutations G48V and V82S 
contribute to improved interactions with substrate. This study gives insight into the dual roles of 
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G48V and V82S as mutations that reduce affinity for inhibitors whilst allowing for more 
favorable interactions with substrates.   
 The clinical isolate PRS5B provides an example of a mutant harboring distal mutations 
with minimal changes in the ligand-binding site. Enzyme kinetics measurements confirmed that 
PRS5B shows intermediate levels of inhibition by clinical PIs while retaining proteolytic 
efficiency and stability in the presence of urea comparable to PRS17 and PR20. Analysis of 
crystal structures of PRS5B bound to APV and DRV suggested that mutation clusters in the 
hinge-loop and Loop 2 regions of PRS5B eliminate interactions throughout the monomer. 
Interestingly, the combinations of mutations in these two clusters exhibit both synergistic and 
antagonistic effects. Molecular dynamics simulations of ligand-free PRS5B confirm the 
conformational variations in the flap, Loop 2, and termini as shown in the crystal structures. In 
the context of other studied variants, these results suggest PRS5B may be representative of an 
intermediate mutant in the selection process towards more synergistic or highly evolved drug-
resistant PR mutants. 
 Crystallographic and enzyme kinetic studies of highly-resistant mutants of PR illustrate 
the molecular mechanisms involved in drug resistance. Structural studies by NMR, 
crystallography, and MD simulations demonstrate that drug-resistant PR mutants possess altered 
conformational dynamics and structural rearrangements. Future work is needed to better explain 
how these changes in protein dynamics in mutants alter drug binding and dissociation. More 
detailed MD simulations combined with neutron vibrational spectroscopy may provide new 
insights into the vibrational dynamics of HIV PR mutants bound with substrate or inhibitors in 
femtosecond to picosecond timescales360–363.  Understanding the details by which mutations can 
127 
directly and indirectly affect inhibitor affinity for the PR ligand-binding site is crucial for efforts 
to design more advanced therapeutics.  
To reach current UNAIDS 90-90-90 targets, major efforts to provide ART to the 
approximately 15 million HIV-infected people not receiving it will undoubtedly have impacts on 
the prevalence of drug resistance364. Structure-based drug design has been successful in 
producing the first and second generation of clinical protease inhibitors. The future of structure-
based drug design for PIs should combine traditional X-ray crystallography with new ligand-
design strategies365 and computational methods366 in order to combat the threat of HIV drug 
resistance.          
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Appendix B: Table of X-ray crystal structures deposited to the protein data bank 
Protein Ligand (Ligand ID) PDB accession code Resolution (Å)  
PRS5B DRV, 1 (017) 6P9A 1.66 
PRS5B APV (478) 6P9B 1.75 
PR20 GRL-142, 2 (7OA) 6PRF 1.21 
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Appendix C: Table of published kinetic inhibition values for highly resistant PR mutants 
PR20, PRS17, and PRS5B 
A dash (-) indicates data not published.  
Appendix D: Python Programs for AMMP Molecular Dynamics analysis  
A 20 ns AMMP molecular dynamics simulation outputs a statistics and coordinate file 
every 10 ps for a total of 2000 individual files. Thus, analysis of MD simulations requires 
automated scripting as a tool to extract desired data. The Python programming language is an 
excellent choice for MD analysis due to a low-barrier learning curve and extensive library 
support. The following section details Python3 programs with selections of code used to analyze 
MD simulations from Chapter 4.  
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Measure_distance.py measures the distance from given CA atoms for a given range of coordinate 
frames. 
  
187 
The script getenergy.py reads AMMP stats.n files and print the mean and standard deviation of 
the binding energy of inhibitors.  
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Visualization of the MD simulations over the timescale are useful for understanding macro 
movements as well as being able to visual follow where specific elements, such as the flap water 
or catalytic hydrogen, are located over the timescale. When executed through the PyMol276 
python interpreter, gif.py creates an image for each .pdb file that can be converted into a .gif 
format for visualization. 
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Appendix F: Lab Manual Chapter: Using Guided-Inquiry Experiments to Characterize 
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Appendix G: Potent HIV-1 Protease inhibitors Containing Carboxylic and Boronic Acids: 
Effect on Enzyme Inhibition and Antiviral Activity and protein-Ligand X-ray structural 
studies  
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